<SEC-DOCUMENT>0001724521-25-000099.txt : 20250806
<SEC-HEADER>0001724521-25-000099.hdr.sgml : 20250806
<ACCEPTANCE-DATETIME>20250806160952
ACCESSION NUMBER:		0001724521-25-000099
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250806
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250806
DATE AS OF CHANGE:		20250806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		251189623

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rcus-20250806.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:38f4330c-9740-4db5-b353-36f858357385,g:64b0e3df-5b47-4fa0-8435-8bea275e9835,d:1ec8f5abfb4a417493029f5a8c422770-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rcus-20250806</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001724521</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rcus-20250806.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-06</xbrli:startDate><xbrli:endDate>2025-08-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1ec8f5abfb4a417493029f5a8c422770_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August&#160;6, 2025</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Arcus Biosciences, Inc.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38419</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-3898435</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(State or Other Jurisdiction</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">3928 Point Eden Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Hayward</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94545</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">510</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">694-6200</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:40.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Trading</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">RCUS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="i1ec8f5abfb4a417493029f5a8c422770_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-23">August&#160;6, 2025</ix:nonNumeric>, Arcus Biosciences, Inc. issued a press release announcing its financial results for the six months ended June&#160;30, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div id="i1ec8f5abfb4a417493029f5a8c422770_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2025q28kexhibit991.htm">Press release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2025q28kexhibit991.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2025q28kexhibit991.htm"> 6, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="i1ec8f5abfb4a417493029f5a8c422770_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:46.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">August&#160;6, 2025</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Terry Rosen, Ph. D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Terry Rosen, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2025q28kexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ic77de2e1f7c34388bd2b6ee467c09c60_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:6pt"><img alt="img230044022_0a.jpg" src="img230044022_0a.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:143px"></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">August&#160;6, 2025</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">PEAK-1, a Phase 3 study evaluating casdatifan + cabozantinib in immunotherapy (IO)-experienced ccRCC, and eVOLVE-RCC02, a Phase 1b&#47;3 study sponsored by AstraZeneca evaluating casdatifan + volrustomig in first-line metastatic ccRCC, have been initiated</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Data from ARC-20 evaluating casdatifan + cabozantinib in IO-experienced ccRCC demonstrated that nearly half of patients had a confirmed response to the combination and that the combination was well tolerated </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">More mature data, including PFS, for the casdatifan monotherapy cohorts in ARC-20 are expected to be presented in the fall, followed by more mature data for the casdatifan + cabozantinib cohort next year</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Overall survival (OS) data from the Phase 2 EDGE-Gastric study, evaluating domvanalimab + zimberelimab + chemotherapy in gastrointestinal (GI) cancers, will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress in October</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Arcus is well positioned to advance its full pipeline with $927&#160;million in cash, cash equivalents and marketable securities at quarter end</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">HAYWARD, Calif. &#8211; (BUSINESS WIRE) &#8211;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Arcus Biosciences, Inc. (NYSE&#58;RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the second quarter ended June&#160;30, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We have now presented data from over 125 patients treated with casdatifan monotherapy or casdatifan plus cabozantinib, which we believe demonstrate the potential for casdatifan to be the best-in-class HIF-2a inhibitor for clear cell RCC,&#8221; said Terry Rosen, Ph.D., chief executive officer of Arcus. &#8220;We are forging ahead with speed and efficiency in our development of casdatifan across multiple ccRCC settings, including our global Phase 3 PEAK-1 trial in the IO-experienced setting and Phase 1b&#47;3 eVOLVE-RCC02 trial in the first-line metastatic setting, the latter in collaboration with AstraZeneca.  With a strong balance sheet and focused investment, we are well equipped to fund casdatifan through data for PEAK-1, which has been designed to enroll rapidly and to achieve a readout as quickly as possible.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Highlights&#58; </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Casdatifan (HIF-2a inhibitor)</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Phase 3 Program&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PEAK-1, a Phase 3 study evaluating casdatifan + cabozantinib versus cabozantinib in IO-experienced metastatic ccRCC, has been initiated. </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eVOLVE-RCC02, a Phase 1b&#47;3 study sponsored and operationalized by AstraZeneca, evaluating casdatifan + volrustomig, an investigational anti-PD-1&#47;CTLA-4 bispecific antibody, in first-line (1L), metastatic ccRCC, has also been initiated.  The study was designed to support initiation of the Phase 3 portion as efficiently as possible.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Data Presentations&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Initial data from the ARC-20 study of casdatifan + cabozantinib in IO-experienced patients with metastatic ccRCC were presented in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">At the time of the data cutoff (DCO, March 14, 2025), treatment with casdatifan+cabozantinib showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up, and almost all patients achieved tumor reduction.</font></div><div style="margin-top:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">At the time of DCO, the vast majority of patients remained on therapy.</font></div><div style="margin-top:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">There was no meaningful overlapping toxicity for the two drugs, and the combination had a well-tolerated safety profile with no patients discontinuing both therapies due to adverse events. </font></div><div style="margin-top:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">This cohort is evaluating the same regimen, in the same setting, as the PEAK-1 Phase 3 study.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Planned Data Readouts&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Fall 2025&#58; More mature data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a TKI.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">2026&#58; More mature data from the casdatifan plus cabozantinib cohort and initial data from the new ARC-20 cohorts evaluating casdatifan in the 1L and IO-experienced settings.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Domvanalimab (Fc-silent anti-TIGIT antibody) plus Zimberelimab (anti-PD-1 antibody)</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Planned Data Readouts&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An abstract describing OS data from the Phase 2 EDGE-Gastric study, evaluating domvanalimab plus zimberelimab and chemotherapy in upper GI adenocarcinomas, has been accepted for presentation at the 2025 ESMO Congress in October. </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The first Phase 3 OS data readout for domvanalimab plus zimberelimab will be from the ongoing Phase 3 study STAR-221, evaluating domvanalimab plus zimberelimab plus chemotherapy in PD-L1 all-comer 1L unresectable or metastatic upper GI adenocarcinomas. Results for this trial are event-driven, and OS data are expected in 2026.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Quemliclustat (small-molecule CD73 inhibitor</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">)</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Orphan Drug Designation was granted by the U.S. Food and Drug Administration (FDA) to quemliclustat for the treatment of pancreatic cancer. </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PRISM-1, a Phase 3 trial of quemliclustat combined with gemcitabine&#47;nab-paclitaxel versus gemcitabine&#47;nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma, is enrolling rapidly, with enrollment completion expected in the third quarter of 2025, well within 12 months of study initiation. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Etrumadenant (adenosine A2a&#47;A2b receptor antagonist)</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2025, we engaged with the FDA regarding promising results from the ARC-9 study evaluating etrumadenant in third-line metastatic colorectal cancer (mCRC)&#59; although the FDA&#8217;s feedback confirmed the potential for a registrational path for this program in third-line mCRC, based on our strategic priorities, Arcus and Gilead agreed to not pursue a Phase 3 study at this time and, in June 2025, Gilead returned its license to etrumadenant to Arcus.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Early Discovery</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Arcus has several research and preclinical programs ongoing that are addressing validated oncology and inflammation targets. Arcus expects that the next development candidate to enter the clinic will be a small molecule directed against an inflammation target.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results for Second Quarter 2025&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cash, Cash Equivalents and Marketable Securities </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">were $927&#160;million as of June&#160;30, 2025, compared to $992&#160;million as of December 31, 2024. The decrease during the period is primarily due to the use of cash in our research and development activities partially offset by the net proceeds from our underwritten offering in February 2025 and the additional $50 million draw down under our term loan facility in June 2025. We believe our cash, cash equivalents and marketable securities, together with available facilities, will be sufficient to fund operations through the initial pivotal readouts for domvanalimab, quemliclustat and casdatifan, which include PEAK-1.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Revenues </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">were $160&#160;million for the second quarter 2025, compared to $39&#160;million for the same period in 2024. The increase in revenue was driven by a cumulative catch-up to revenue of $143 million relating to pausing future development of etrumadenant and Gilead's related return of its license to the program. Arcus expects to recognize GAAP revenue of between $225 million and $235 million for the full year 2025, which includes the cumulative catch-up.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Research and Development (R&#38;D) Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> were $139&#160;million for the second quarter 2025, compared to $115&#160;million for the same period in 2024. The net increase of $24 million was primarily due to increased CMC costs. We expect to incur elevated CMC costs through the third quarter of 2025. Otherwise, clinical costs for our late-stage programs were flat, as increased enrollment and start-up activities for PRISM-1 and PEAK-1 were largely offset by lower costs for STAR-221. Other increases in expense resulted from an increase in early-stage development activities, driven by Phase 2 activities for casdatifan. Non-cash stock-based compensation expense was $8 million for the second quarter 2025, compared to $10 million for the same period in 2024. For the second quarters 2025 and 2024, Arcus recognized gross reimbursements of $33&#160;million and $40&#160;million, respectively, for shared expenses from its collaborations. R&#38;D expenses by quarter may fluctuate due to the timing of clinical manufacturing and standard-of-care therapeutic purchases with a corresponding impact on reimbursements. Arcus expects R&#38;D expenses to decline commencing in the fourth quarter 2025 as costs related to the domvanalimab Phase 3 development program decrease significantly.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">General and Administrative (G&#38;A) Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> were $29 million for the second quarter 2025, compared to $30 million for the same period in 2024. The decrease was primarily driven by a decrease in compensation and personnel costs driven by lower stock-based compensation, partially offset by increased costs recognized in the quarter in connection with the Gilead Agreement. Non-cash stock-based compensation expense was $7&#160;million for the second quarter 2025, compared to $10 million for the same period in 2024.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Net income (Loss)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> was $&#8212;&#160;million for the second quarter 2025, compared to a $93 million net loss for the same period in 2024.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About Arcus Biosciences</font></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and&#47;or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences&#8217; clinical and preclinical programs, please visit www.arcusbio.com.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Domvanalimab, quemliclustat and zimberelimab are investigational molecules, and neither Gilead nor Arcus has received approval from any regulatory authority for any use globally, and their safety and efficacy have not been established. Casdatifan, etrumadenant, AB598 and AB801 are also investigational molecules, and Arcus has not received approval from any regulatory authority for any use globally, and their safety and efficacy have not been established.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About the Gilead Collaboration</font></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Arcus established a 10-year collaboration with Gilead to strategically advance our portfolio. Under this collaboration, Gilead obtained time-limited exclusive option rights to all of our clinical programs arising during the collaboration term. Arcus and Gilead are co-developing three investigational products, including zimberelimab (anti-PD-1 molecule), domvanalimab (anti-TIGIT antibody), and quemliclustat (CD73 inhibitor). The collaboration was expanded in November 2021 and May 2023 to include research directed to two targets for oncology and two targets for inflammatory diseases. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Rosen&#8217;s quote and the timing of future data readouts and data presentations. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus&#8217;s actual </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to&#58; risks associated with preliminary and interim data not being guarantees that future data will be similar&#59; the unexpected emergence of adverse events or other undesirable side effects in Arcus&#8217;s investigational products&#59; difficulties or delays in initiating or conducting clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials&#59; difficulties associated with the management of the collaboration activities&#59; changes in the competitive landscape for Arcus&#8217;s programs&#59; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the &#8220;Risk Factors&#8221; section of Arcus&#8217;s most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Investor Inquiries&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pia Eaves &#160;&#160;&#160;&#160;<br>VP of Investor Relations &#38; Strategy<br>(617) 459-2006<br></font><font style="color:#0563c1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">peaves&#64;arcusbio.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Media Inquiries&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Holli Kolkey<br>VP of Corporate Affairs<br>(650) 922-1269<br></font><font style="color:#0563c1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">hkolkey&#64;arcusbio.com</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Maryam Bassiri</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">AD, Corporate Communications</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(510) 406-8520</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">mbassiri&#64;arcusbio.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><div id="ic77de2e1f7c34388bd2b6ee467c09c60_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> (In millions, except per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">License and development services revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">152&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">172&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">163&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Other collaboration revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">11&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">16&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">160&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">39&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">188&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">184&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">139&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">115&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">261&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">224&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">29&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">30&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">62&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Impairment of long-lived assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">168&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">145&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">318&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">306&#160;</font></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(106)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(130)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(122)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-operating income (expense)&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Interest and other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Interest expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total non-operating income, net</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">25&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Income (loss) before income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(93)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(112)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(97)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income (loss)</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(93)</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(112)</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(97)</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income (loss) per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1.02)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1.09)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1.09)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1.02)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(1.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Shares used to compute net income (loss) per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">106.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">91.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">102.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">88.6</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">106.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">91.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">102.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">88.6</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div><div id="ic77de2e1f7c34388bd2b6ee467c09c60_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Selected Consolidated Balance Sheet Data</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> (In millions)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">927&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">992&#160;</font></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">1,075&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">1,150&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">526&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">665&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">549&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">485&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Derived from the audited financial statements for the year ended December&#160;31, 2024, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February&#160;25, 2025.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rcus-20250806.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:38f4330c-9740-4db5-b353-36f858357385,g:64b0e3df-5b47-4fa0-8435-8bea275e9835-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rcus="http://arcusbio.com/20250806" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://arcusbio.com/20250806">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20250806_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20250806_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://arcusbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rcus-20250806_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:38f4330c-9740-4db5-b353-36f858357385,g:64b0e3df-5b47-4fa0-8435-8bea275e9835-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_350af85b-b07c-438b-8062-57961e8680c9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9f2a86f7-cb00-4512-9720-8e5b4b954256_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_877440c5-f7b2-4467-8205-ea8629030a92_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f7a226ac-a162-4af2-85db-b3ee347abf94_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0f6a1fc6-ad89-4386-bf14-c6e91c7f5d2f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ac81dc51-17b4-4e81-a4d5-28270057899d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ce0269a1-2ec4-4634-bdee-335419e9fa36_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9d4448c8-1241-4d64-99b6-a708cbc38537_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_811b67ef-447d-45d5-85ee-0c288c279279_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_19925f30-b3f3-4069-b745-91b6d0dce67e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a62451a4-4458-4f65-b3fb-db53b17bbf6c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8edb18fe-11b1-439f-8c25-225c5b5723f4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3f802779-3de9-4b2a-965c-2ae0e81e75ab_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f8f9240f-4800-4a21-8f14-0544b843d2a5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bb17d0b0-e74c-41a5-b75d-b0224122fc62_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ffba2394-fcb0-422b-a557-f31d3d783a06_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5e5f7b86-24c8-4e4a-a9b6-8456b0d5d4e0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8cf0a323-30a7-46a9-84a8-5d0aacefc475_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_49a3cc05-808b-4a82-b2cd-7bca37e989b2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_260f37ee-3b68-4cfb-b1a6-79ae5011693f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_be0b3bf6-7287-4311-965d-7a5069a3c2f8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7531b967-45ce-4caa-b684-96b3462b61ec_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f0abbe75-4fc4-4a02-93de-a01e30bad1d3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rcus-20250806_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:38f4330c-9740-4db5-b353-36f858357385,g:64b0e3df-5b47-4fa0-8435-8bea275e9835-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcusbio.com/role/Cover" xlink:type="simple" xlink:href="rcus-20250806.xsd#Cover"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_00d7ad93-1b3a-46bb-be02-50412962e952" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_DocumentType_00d7ad93-1b3a-46bb-be02-50412962e952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4c1adc25-2a81-47c0-bc96-f938ff5071a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_DocumentPeriodEndDate_4c1adc25-2a81-47c0-bc96-f938ff5071a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_720f5ad3-113e-438a-b554-cf9f3d4d22e6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityRegistrantName_720f5ad3-113e-438a-b554-cf9f3d4d22e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c40c6fff-e1c0-4454-96f1-d2f09347a267" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c40c6fff-e1c0-4454-96f1-d2f09347a267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ab844ca1-8a50-45b1-ac89-54d195bfc9ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityFileNumber_ab844ca1-8a50-45b1-ac89-54d195bfc9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_37e96e3c-391d-42b4-90a4-47135cabbbc1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityTaxIdentificationNumber_37e96e3c-391d-42b4-90a4-47135cabbbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bf4242e3-6981-448d-ac11-6af58adba7f9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityAddressAddressLine1_bf4242e3-6981-448d-ac11-6af58adba7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c5f6bb7b-887e-4c87-8c86-688d39ace0ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityAddressCityOrTown_c5f6bb7b-887e-4c87-8c86-688d39ace0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_be8a6d7d-58e6-4ad1-9222-67271e455037" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityAddressStateOrProvince_be8a6d7d-58e6-4ad1-9222-67271e455037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_992bfe6c-7b50-45f6-87ac-1d11d20796d8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityAddressPostalZipCode_992bfe6c-7b50-45f6-87ac-1d11d20796d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_02b03e9c-fc6c-454f-b5bf-c7fb08e2b548" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_CityAreaCode_02b03e9c-fc6c-454f-b5bf-c7fb08e2b548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_478ff629-fdce-45b2-bb58-cade46a89077" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_LocalPhoneNumber_478ff629-fdce-45b2-bb58-cade46a89077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_498eca86-29c5-43f2-9325-da154f019f93" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_WrittenCommunications_498eca86-29c5-43f2-9325-da154f019f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_4b4c2770-f633-47d9-ac6d-048e1c98a6e5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_SolicitingMaterial_4b4c2770-f633-47d9-ac6d-048e1c98a6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_9376b677-c583-450c-9832-6290ebca1123" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_PreCommencementTenderOffer_9376b677-c583-450c-9832-6290ebca1123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_0f790d12-4bd1-425e-9585-c5b7526f0b8c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_0f790d12-4bd1-425e-9585-c5b7526f0b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2bb4f8a0-a5b9-45fc-a6b4-0654a7598e27" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_Security12bTitle_2bb4f8a0-a5b9-45fc-a6b4-0654a7598e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7674303d-6e98-4346-9101-1f1b8026b40a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_TradingSymbol_7674303d-6e98-4346-9101-1f1b8026b40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a65092b5-4f8c-456a-a502-6a803ed065b9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_SecurityExchangeName_a65092b5-4f8c-456a-a502-6a803ed065b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_401c7c09-607d-4647-9499-f9f1f67e3579" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityEmergingGrowthCompany_401c7c09-607d-4647-9499-f9f1f67e3579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3578bfb0-db62-4e48-994d-a4640d005483" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_AmendmentFlag_3578bfb0-db62-4e48-994d-a4640d005483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2b220ed5-5490-40d9-b60b-1be3e71779cf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_17a9e39f-222a-408b-9730-ea01e875dceb" xlink:to="loc_dei_EntityCentralIndexKey_2b220ed5-5490-40d9-b60b-1be3e71779cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img230044022_0a.jpg
<TEXT>
begin 644 img230044022_0a.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Z!#L# 2(  A$! Q$!_\0
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MKR#FCFCFCFO:,0YHYHYHYH _17_@E)\5MT7BSX<W<W*D:UIZL>QVQ3J/_()
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M%O,+<VV<#./XTR<!UXY .#Q7KE?,5*<J<G":LT="=]4%%%%9C"BBB@ HHHH
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MRC)QG&#V)KOZ_GL\/>)-5\(ZQ;:MHFHW6DZG;-OAN[.5HI8SZAE.:^T? _\
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MRJG_ '5%>W45\E7S#$XA^]*R[+0ZE",>A7L=/M=+MUM[.VAM+=?NQ01A%'T
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MO3AS:LT_#_A_3?">B66CZ-8P:;I=E$(;>TMD"1Q(.@ %:-%%?":O5G8%%%%
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MG460D$6L0WR#(Z%@ @/8N*_<BSLX-/M(+6UACMK:!%BBAA4*D:*,*J@<
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M'IN!\QNGWU!'R"OK&FHBQJJ(H55& JC  IU?F5>M+$5)59;L]&*Y59!1116
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M4 %%%% !1110 4444 %?D5_P4V_Y.>G_ .P1:?\ L]?KK7Y%?\%-O^3GI_\
ML$6G_L]>]DO^]?)_H8UOA/E#FCFCFCFONCB.A^'?_)0/#/\ V%+7_P!'+7]
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MV,H3'DR(JCYWVDJ=S+PB>E1?#G_@EY\,_"YCG\4:AJGC*Z4@M&[_ &.V./\
M8C.__P B5]E45Z"Q^)C35*,[)?UN1R1O>QS'@3X9^$_ACIKV'A/P[IWA^UDV
M^8MA;K&92,X+L!ER,GEB3S73T45P2DY.\G=EA1112 **** "BBB@ HHHH **
M** "BBB@ K\[O^"KGQ8POA/X<6DW7.M:@JG_ 'HK=3_Y&8@^B'TK]#I94MXW
MEE=8XT!9G8X"@<DD]A7X2_M%_%)_C-\:O%?BW>S6M[>,MF&XVVL8$<(QV.Q5
M)]R37O9-0]KB/:/:/Y]#&K*T;'G'-'-'-6-/T^YU;4+:QLX6N+NZE6&&&,99
MW8@*H]R2!7W1Q'Z6_P#!*KX5?V1X'\2^/[N'%QK%P-.LF8<BWAYD93Z-(VT^
M\-?=]<9\&_AW;?"7X6^&/"%KM*:38QV\CH,"27&99/\ @4A=O^!5V=?F>+K?
M6*\JG=_AT/1BN5)!1117&4%%%% !1110!S?Q(\$6?Q)\ ^(?"VH<6FL6,MF[
M8R4WJ0''NIPP]P*_ [Q#H5YX7U[4M&U&(P:AIUS):7,1_@DC<HZ_@0:_H5K\
MCO\ @I1\)SX!^/K^(K:'R]+\5VXO491A1<H DZCW^Y(?>6OILDK\M25%]=5Z
MK^OP.>M'2Y\F<T<T<T<U]D<@<U]1?\$Z?BO_ ,*Y_:(T_2[F;R]+\41'290Q
M^43D[K=L=SO'EC_KJ:^7>:L:;J5SH^HVM_93-;7EK*D\$T9PT<BD,K#W! /X
M5A7I*O2E3?5%1?*[G]#E%<1\(?B99?%+X3^&O&D4D4,&J6,=Q-\V$AEQME3)
M_NR!U_X#57Q'^T%\,O".1J_C_P .6,B]8GU.$R?]\!BWZ5^9^SGS."6J/0NM
MST&BOG?7/^"@'P*T/*GQJ+^0?P6-A<R_^/>7M_6N*U3_ (*B?!ZQW"WM?$NH
MD=/L]A&H/_?<J_RKHC@L3+:F_N)YX]SZ]HKX;N_^"L/@),_9?!OB.8?]-FMX
M_P"3M6;)_P %:/#2Y\OX?:LWINOXE_\ 936RRW%O_EW^0O:1[GWM17P,G_!6
MGPZ?O?#W5!_NZC&?_9*Z'PA_P5&\(>*O$FDZ-_PA>MVL^HWD-FDGGPNJM(X0
M$\C@$T/+<7%7</R#VD>Y]L4445YAH%?D5_P4V_Y.>G_[!%I_[/7ZZU^17_!3
M;_DYZ?\ [!%I_P"SU[V2_P"]?)_H8UOA/E#FCFCFCFONCB.A^'?_ "4#PS_V
M%+7_ -'+7] =?SU>']6;0->TW5$B6=[*YCN5B<D*Y1PV"1V.*^X_^'L_BK_H
M0='Q_P!?DO\ A7SN:X.MBI0=)7M<Z*<E&]S],J*_,W_A[/XJ_P"A"T?_ ,#)
M?\*/^'L_BK_H0M'_ / R7_"O"_LC%_R_BC;VL3],J*_,W_A[/XJ_Z$+1_P#P
M,E_PH_X>S^*O^A"T?_P,E_PH_LC%_P OXH/:Q/TRHK\RI/\ @K-XM*_)X#T5
M3_M7<QK.O/\ @J]\0Y%/V7PAX9A/8RBXD_E*M']D8O\ E_%![6)^HU(S!5))
MP!R2:_(O6O\ @II\:=45A;7.AZ.3T:STT,1_W]9Z\7^('[1OQ-^*,+P>)_&V
MKZG:2??L_/\ )MV^L4>U#^5=-/)*\G[\DE]Y+K+H?J-^T!^WI\._@O:W5EIM
M[%XQ\4J"L>FZ7*&AB?\ Z;3#*H!W5=S>PZU^5WQF^-GBOX\>,IO$?BN_^TW)
M&RWM8@5M[2+.1'$F3M7\R3R23S7!\T<U])A,OHX/6.LN[.>4W(.:.:.:EM+2
M?4+J&VM89+FYF<1Q0PH6=V)P%4#DDGL*](S(N:_2K_@G/^R3/X9BA^*WB^R,
M.I7,)&@V,ZX:")QAKI@>C.IP@[*Q/.Y<9O['/_!/*33[JR\:_%>Q3S8RLUAX
M7F 8 ]5DNATXZB+_ +[[K7Z&5\EF>9*2="B_5_HCJIT^K"BBBOE#I/-_VD?$
MS>#_ (!?$'5D;9-;Z)=")LXQ(T;(A_[Z85^$?-?LO_P4'U8Z3^R;XT"'#W36
M=L/HUU%G_P =!K\:.:^TR.-J$I=W^AR5MT'-'-'-'-?2'.6](TV36-6LK"'F
M6ZG2!..[,%'ZFOZ#]+TZ'1],M+"W7;;VL*01KZ*JA0/R%?@]\!]._M;XW_#Z
MR(W"X\0:?&5]C<1@_I7[UU\CGLO>IQ]?T.JCU"BBBOE3I"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@##\<_\B3X@_P"P?<?^BVK^
M??FOZ"/'/_(D^(/^P?<?^BVK^??FOKLA^&I\OU.6MT#FCFCFCFOJCF/L[_@E
M3_R7_P 0?]BW-_Z4VU?JM7Y4_P#!*G_DO_B#_L6YO_2FVK]5J^"SC_>GZ([:
M7PA1117B&P4444 %%%% !1110 4444 %%%% 'X]?\%(O^3JM?_Z\;+_T0M?,
M'-?3_P#P4B_Y.JU__KQLO_1"U\P<U^EX+_=J?HOR."?Q,]N_8H_Y.F^'7_80
M/_HIZ_;:OQ)_8H_Y.F^'7_80/_HIZ_;:OE\\_CQ]/U9T4?A"BBBOG#<****
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M&7FOLS_@J!\5_P#A+OC-I_@ZTFWV'A>TQ,JG@W<X5WZ=<1B$>QWBOC/FOO\
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M[J*X26&$JZ,CA@RX7J".*VCQO.I[KRZJK_X?\T92R>G%76)@_O/J>BBBLCS
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M"_[!OP.\*LKQ>!X-2F4Y\S5+F:YS]4=]G_CM>T^&_"&A>#K,6F@Z+I^B6O\
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M:^L/*&R1K-&R-G:P*G!P:_9?]CF[\-_%WX!^%O$,]DEYK$, T[4FGD+G[1
MC,1]T;U"R8QP)!UK\:N:^\_^"5/Q6_LOQAXF^'UY-B#58!JEBK'@3Q8655'J
MT95OI#7S6?9=0QV'4ZU-2=/572=K[VO\ON.W#8BK0DU3DXWWL['Z26>C6&G
M"ULK>VQT\F)5_D*NT45\3"$::Y8*R.B4I2=Y.X44459(4444 %%%% !7Y%?\
M%-O^3GI_^P1:?^SU^NM?D5_P4V_Y.>G_ .P1:?\ L]>]DO\ O7R?Z&-;X3Y0
MYHYHYHYK[HXCH?AW_P E \,_]A2U_P#1RU_0'7\_GP[_ .2@>&?^PI:_^CEK
M^@.OD,]^*G\_T.JCLPHHHKY8Z3Y9_;J_91C^/G@K_A(- ME_X3S1(3]EV@ W
M]N"6:V8_WN2R9Z,2. Y(_(.:&2WF>*5&CE1BK(XPRD<$$=C7]$5?F]_P4<_9
M+_LVYNOBUX2LO]&N'W>(;*%?]7(>!=J!V8\28_B(?G<Y'U&48[D:PU1Z/;_(
MYZL/M(_/SFCFCFCFOL#D.J^&'Q,U_P"#_CC3/%?AJ[^R:I82;EW9,<J'AHI%
MS\R,,@CWX(."/VR^ 7QST#]H+X=V7BC0W\IV_=7VGNX:2RN  6B;U'.5; W*
M0<#H/PCYKV#]F#]HW6/V;?B-%K=F)+O1;O;!J^EAL"Z@!ZC/ D3)*M[D=&;/
MC9E@5BX<T/C6WGY&U.?*]=C]Q**P_!7C/1_B'X5TOQ)X?O8]1T?4H5GMKB/H
MRGJ".H8'*E3R""#R*W*^!:<79G:%%%%( HHHH **** /!OVZ-%_M[]E+X@0!
M=S0VL5V/;RKB.0G\D-?BIS7[]_%+PO\ \)Q\,_%GAW;O.JZ5=62K_M21,H_4
MBOP%96C9E92K*<$$8(K[+(IWI3AV?Y_\,<E;=,3FCFCFCFOICG+6EZA)I.J6
M=]#_ *ZUF29/]Y6!'ZBOZ#])U*'6=*LM0MSNM[N%)XSZJRAA^AK^>;FOV^_8
MY\;#Q[^S/X U(R>9-#IRZ?,>^^W)@.?<^6#^.:^7SVG>$*G9M??_ ,,=-%ZM
M'LU%%%?'G4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &'XY_Y$GQ!_V#[C_T6U?S[\U_01XY_P"1)\0?]@^X_P#1;5_/OS7UV0_#
M4^7ZG+6Z!S1S1S1S7U1S'V=_P2I_Y+_X@_[%N;_TIMJ_5:ORI_X)4_\ )P'B
M#_L6Y_\ TIMJ_5:O@LX_WI^B.VE\(4445XAL%%%% !1110 4444 %%%% !11
M10!^/7_!2+_DZK7_ /KQLO\ T0M?,'-?3_\ P4B8-^U9KX!SBRL@?^_"U\P<
MU^EX+_=J?HOR."?Q,]N_8H_Y.F^'7_80/_HIZ_;:OQ)_8H_Y.F^'7_80/_HI
MZ_;:OE\\_CQ]/U9T4?A"BBBOG#<***Y7Q;\5/!G@.-V\2>*]&T/;U6_OHH6_
M!6;)/T%5&+D[15P.JHKSCX:_M#_#SXQ:YJ>D>#O$MOKM]IL2SW*012*H1F*@
MJS* XR.=I.,CUKT>G*$J;Y9JS%>^P4445 PHHHH **** *>J:18ZY8R6>I65
MOJ%G(,/;W42RQM]58$&O OB)^P+\%_B%YDO_  C'_"-WCY_TGP_*;7&?^F>#
M%_XY7T316U.M4HN].30FD]S\U_B+_P $H-9LQ+/X'\96NHIC*V6MPF"3Z>;'
MN#'ZJHKY5^)W[,'Q0^$/FR^)O!VH6UC'UU"V07-KCU,L995_X$0?:OW2I&4,
M"",@U[-'.<13TG:2^XR=*+V/YW.:.:_:OXO?L2_"?XQ+//>^'8]#UB7)_M70
MP+6;=CJR@;'/3EE)XZU\#_'C_@G+\0?A;'<ZIX8/_"=:!'ER;&(I>PJ,GYH,
MG?@=XRQ[[17T.'S7#XCW6^5^?^9A*G*)\F<T<TZ2-H9&1U9'4[65A@@CJ"*;
MS7L&(<UI>&_$FJ>#]?L-;T6^FTW5;&99[:Z@;#QN#P1_@>""0:S>:.:32:LQ
MG[<?LF_M&67[2'PO@U@B*V\1V!6UUFQC/$<V,B11U$<@!9?3#+DE2:]LK\6/
MV(_CA)\$/CMH]Q<W/D^'M:9=+U56;"".1@$F/8>6^UL]=N\#[U?M/7Y[F6$^
MJUK1^%ZK_([:<N9!1117E&H4444 %%%% !1110 4444 %?B_^WA\6/\ A:W[
M1WB%[>;S=*T,C1;/!XQ"3YK#L<RF4@]QMK]5/VDOBHGP7^"/BSQ8)%2\M+0Q
MV(/.;J0B.'CN [*3[*:_"F21II&=V9W8[F9CDDGJ2:^IR.A=RKOIHOU.:M+H
M-YHYHYKM?@K\.;CXN?%CPMX0MPW_ !-KZ.&5TZQP@[IG'^[&KM_P&OK924(N
M4MD<V^A^J_\ P3W^%7_"M?V<-'N[F'R]4\2.VLS[ASY;@" 9]/*5&QV+M7TQ
M4%C90:;96]G:Q+;VMO&L4448PJ(H 50/0 "IZ_+ZU5UJDJCZL]%*RL%%-9EC
M5F9@JJ,EB< "OA?]JK_@HYIW@MKSPO\ "V2WUC7$)BG\0,!+9VIZ$0CI,X_O
M?<'^WR!>'P]7$SY*:N*4E%79]*?'C]I;P/\ L\Z+]K\3ZENU&5"UIH]IA[NY
M_P!U,_*N?XV(7C&<\5^6W[1G[;/CS]H&:YT]K@^&_"+,0FAZ?(<2KV\^3@RG
MVP%_V<\UX9XD\2ZMXQUR[UG7-1N=5U6[?S)[N[D,DDC>Y/Z#L!BLWFOML'EE
M+"VE+WI=_P#(Y)5'(.:3W[5H^'/#>K>,-<M]'T'3;C5]5G_U=K:KN;'=F/1%
M'=F( K[!^#_[%^D^'_(U7QZ\/B'5!ATTB$DV$!ZXD/!G8>^$XZ&O.S[B;+>'
M:?-C)^^]H+63^71>;LOGH=^ RS$YC/EH1TZM[+^NQ\V_"WX%>,/C!*LNB6 M
MM'W;9-:U#,=HOKL.,RGV0'ZBOL/X6?LH^"OANT%[>0?\)7KT?S"^U.,&*)O6
M*#E5^K;F]Z^@/"O@W4/$TL=KIEJL=M"!'O"A((%[#@8 Q_"!^%>W^$/A?I7A
M94G=?M^H#G[1*O"G_87M]>M?AV)SSB'C%N&'?U?#/LWJO.6CEZ+ECW1]K'"9
M9D:O6_>U>W;Y;+YW?8\P\+_"?6/$GESW>=.LR!AYA\[#_93T^N!7KGAGX>Z+
MX757MK8370ZW,_SOGV[+^%=-17M97PW@,K2E"/-/^9ZOY=%\M?,\/&YQBL;[
MLI<L>R_7N%?A?^U%\,?^%/\ QZ\8^&HXO)L8;UKBQ4#C[-*!+$!Z[5<*?=37
M[H5^='_!5[X8[+CP=\0;:+APVB7K@=QNE@/U(,XS_LK7Z/D];V>(Y'M+\SYZ
MJKQN?GES1S1S1S7W1Q!S79_!GXC7/PD^*GA?Q?:[BVDWT<\B(<&2'.V6/_@4
M;.O_  *N,YHYJ914HN+V8]C^AO3M0MM6T^VOK.9;BTN8EFAFC.5=& *L/8@@
M_C5FOF#_ ()V_%;_ (61^SIIFG7,WF:IX8E.D3!C\QA4!K=L>GEL$'_7,U]/
MU^85Z3H594WT9Z,7=7"BBBL!A1110 4444 %?D5_P4V_Y.>G_P"P1:?^SU^N
MM?D5_P %-O\ DYZ?_L$6G_L]>]DO^]?)_H8UOA/E#FCFCFCFONCB.A^'?_)0
M/#/_ &%+7_T<M?T!U_/Y\._^2@>&?^PI:_\ HY:_H#KY#/?BI_/]#JH[,***
M*^6.D*KWUC;:G97%G>01W5I<1M#-!,@=)$8$,K*>"""00?6K%% 'XS_MJ?LL
MW'[.?C[[1ID4DW@C67:33+@Y;[.W5K5V/\2]5)^\N#DD-CYSYK]\OB[\*M!^
M-/P_U7PEXB@\VPOH\+*@'F6\H^Y-&3T=3R.QY!R"0?Q%^-'PAUWX&?$35/"/
MB"+%U:-NAN$4B.Z@;/ES1^JL!^!#*>017WF68[ZS#V<W[Z_%=_\ ,XJD.5W1
MP_-'-'-'->X8GU7^PO\ M<2_ ?Q8/#7B2Z9O 6KS#S68D_V;.< 3J/[AX#CT
M 8<KAOUUM[B*Z@CFAD6:&10Z21L&5E(R"".H(K^=_FOT*_X)V_M@?96L/A+X
MSO?W3MY7A[4;AONL>EF['L3_ *O/<[.Z ?+YME_.GB*2UZK]3IIS^RS]&J**
M*^/.H**** "BBB@ K\,/VJ/ )^&?[0GCK01'Y5O'J4ES;+C@038FC ]<+(!^
M!K]SZ_-K_@JU\*VL]>\)_$.UA_<7D1T>^=1@"5-TD)/J64RCZ1"O>R:M[/$<
MC^TOQ,:JO&Y\ <T<T<T<U]T<0<U^E/\ P2C^):WOA;Q?X#N)?W]A<+JUHC'D
MQ2 1R@>RLD9^LM?FMS7K_P"R;\8O^%'_ !W\-^([B4Q:0\OV'4^>/LLN%=CZ
M[#MDQZQBO/Q]#ZQAY06^Z^1I"7+*Y^XM%-5ED565@RL,A@<@BG5^;G>%%%%
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M0*?%KX0Q>&-3N0_B;PJB6D@=OGGL\8@E'K@#RVZ\HI)^<5]85^#?P)^,VL?
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M+7] =?S]?#^01>/?#;M]U=3MB?PE6OZ!:^1S[XJ?S_0ZZ/4****^5.@****
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M444 %%%% !1110 45!>7EOI]K-=7<\=M;0J7DFF<(B*.26)X 'J:^)?VDO\
M@I5X?\&QW.A_#$0^)];YC?69 386YQUC[S,/;"=#ENE=-##U<3+EI*Y,I*.Y
M]%_M ?M)>#OV=/#)U'Q'>>;J,R-]@T:W8&YO&']T?PH#U<\#W. ?Q\^/G[0'
MBK]H?QH^O>)+G;!'N2PTR%C]GLHB<[4'<G W.>6('8 #C_&GC?7OB)XBN]>\
M2ZK<ZSJ]TV9;JZ?<Q] .RJ.@4  #@ 5B<U]Q@<NA@US/67?_ "..=1R] YKN
M_@G\&_$'QW^(6G^$_#L.ZYN#YEQ=.#Y5I "-\TA[*,CZDJHY(K-^&7PR\1?%
M[QE8^&/"^GOJ&JW;< <)$@QNDD;^%%SDL?IR2 ?V7_9B_9IT#]FOP*NE:?MO
MM=O LFJZNR8>YD X5?[L:Y(5?<D\DFGF&/C@X66LWLOU"G#F?D=?\'_A-H/P
M2^'NE>$?#T'EV-DGSS.!YMS,>7FD(ZLQ_ # &  !VM%%?G\I.<G*3NV=VP44
M45(!7R+_ ,%*O@X_Q"^!\?B>P@,VJ^$IFNVVC+-9N MP!_N[8Y">RQM7UU4%
M]8V^IV5Q9W<$=S:W$;130RJ&21&&&5@>H()!'O71AZSP]6-6/0F2YE8_GBYH
MYKVG]K3]GF\_9U^+%[HZQR/X<OBUWHMX^2)+<M_JRW=XR=K=S\K8 85XMS7Z
M93J1JP52#T9Y[5G9AS7UO_P3W_:@@^"_CJ;PGXCNQ;^$/$4J_P"D2MB.QO.%
M24GH$<81SVPC$@*:^2.:.:BO1CB*;ISV8XR<7=']$E%?FG^Q7^W]'X3L['P%
M\3KQVTF(+!IGB&3+&U7HL-QW,8X"R?P]&^7E?TFM+N#4+6&YM9H[FVF19(IH
M6#(ZD9#*1P000017YUBL+4PD^2:]'W.Z,E)71-1117&6%%%% !1110 445QW
MQ2^+GA/X,^%YM?\ %VKPZ58KD1JYS+<.!GRXD'+L?0=.IP,FJC%S:C%7; V?
M%WBS2/ OAO4?$&O7\.F:/I\+3W-U,<*BC]22< *.22  20*_%']J/]H/4/VC
MOBE>>(IEDM-'MU^R:382$?N+<$D%@.-[DEF//) R0HKI_P!J_P#;$\0_M*:P
MME&DFB>"[.4O9Z0KY:5AD":<CAGQT ^5 2!DY9OGKFON,LR_ZJO:U?C?X''4
MJ<VBV#FNU^"_POO_ (S?%'P[X.T_<LNJ72QRS*,^1"/FEE_X"@9O?&.]<5S7
MZF_\$V?V;9/A[X-F^(VOVIBU[Q% $T^*1<-;V!(8-[&4A6_W53^\17=CL4L+
M1<^O3U(A'F=C[)T/1K/PYHMAI.G0+;:?8V\=K;PITCC10J*/8  ?A5ZBBOS?
M?5G>%%%% !7Y2?\ !4KPG_8_Q\TG6D7$6L:+$S-CK+%(\;?^.>57ZMU\$_\
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M:B_9UTK]I'X:W&A71CM-;M2UQI&I,.;:?&,,1SY;X"L.>QQE5K\4?%?A75?
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M[17XO:+^WU\==#C")XYDNT QMO;&VF/_ 'TT>[]:UYO^"CGQUD3:OB:RB/\
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M@AXJ_P# ^'_XQ1_PZU^#_P#T$/%7_@?#_P#&*/[9POG]P>RD?D[S1S7ZQ?\
M#K7X/_\ 00\5?^!\/_QBC_AUK\'_ /H(>*O_  /A_P#C%']LX7S^X/92/R=Y
MHYK]8O\ AUK\'_\ H(>*O_ ^'_XQ1_PZU^#_ /T$/%7_ ('P_P#QBC^V<+Y_
M<'LI'Y.\T<U^L7_#K7X/_P#00\5?^!\/_P 8H_X=:_!__H(>*O\ P/A_^,4?
MVSA?/[@]E(_)WFOWU^#W_)(_!'_8#L?_ $G2OFS_ (=:_!\_\Q'Q5_X'P?\
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M_!__ *"'BK_P/A_^,4?VSA?/[@]E(_)WFCFOUB_X=:_!_P#Z"'BK_P #X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"&V?@G_P!#Y:_^ ES_ /&J /<**\T^'W[2'PW^*GB Z)X5\40:OJGDM/\
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M*** "BBB@ HHK!\;^.-#^''AF[\0>)-032]'M2@FNI$9@F]PB\*">68#@=Z
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M *635\+_ /!0[_DYK5_^O"S_ /10K[H_87_Y-7\#_P"Y=_\ I9-3 ]YHHHI
M%%%% &#X^_Y$3Q'_ -@VY_\ 135^'GA/PW<>,?%6C:!9R117>JWL-C#).2(U
M>6144L0"0 6&< \5^X?C[_D1/$?_ &#;G_T4U?B]\#?^2V?#_P#[&'3_ /TI
MCJD!]$_\.P_B7_T,/A7_ ,"+G_XQ1_P[#^)?_0P^%?\ P(N?_C%?IM12N!^9
M/_#L/XE_]##X5_\  BY_^,4?\.P_B7_T,/A7_P "+G_XQ7Z;447 ^,?V2_V+
M?&7P$^*S>)]=U;0[VQ.GS6GE:?+,TFYV0@X>)1CY3WK[.HHI %%%% !7(?&+
M_DD?C?\ [ =]_P"D[UU]<A\8O^21^-_^P'??^D[T ?AQS7VG_P $\OVDO^$3
MUY?AGX@NL:/JLV[2)I6XM[MCS#ST64]!_?[9<FOF[]G?2[/7/CEX&TW4;6&^
MT^\U:WMKBVN$#I+&[A64@^H)K:_:8^!>H?L\_%2ZTA3,VD3M]LT>_)P9("W
M+#_EHA^5NG(#8 850'[-45\\_L8?M')\>/ARMKJEPI\8:(J0:BK<-<IC"7('
M^UC#8Z,#P 5KZ&J0"BBB@#\\O^"I_P#R,7P]_P"O6\_]#BKO/^"7?_)*_%W_
M &&1_P"B$K@_^"I__(Q?#W_KUO/_ $.*N\_X)=_\DK\7?]AD?^B$I] /M&BB
MBD 4444 %,DD2&-Y)'6.- 69F.  .I)]*?7P7_P40_:8GL&D^%7AN[:)Y(UD
MUZZA;#;&&4M0?0J0S^H95S@N* *G[3W_  4*F2ZN_#'PKG58XRT5SXE*AMYZ
M$6P/&/\ IH>O\(Z,?EKX;?!'XD_M(:]<W>D65YK#R2?Z9KFIS,(5;U>9\EFZ
M<#<WM7H7[&_[)LOQ]UR36]>$MKX'TV79.T9*O?3  ^0C=E (+L.0" .3E?U2
MT'0=-\+:/::3I%C!INF6D8B@M;:,)'&H[ #_ #S3V ^&_!W_  2WM5MTD\5^
M.)GG/WK?1[4*J_220DG_ +X%=G+_ ,$P_AHUMLC\0^*$F_YZ-<6Y'Y>3_6OL
M&B@#\Y/B5_P3%\0Z3;RW7@CQ+;Z\%&1I^I1_99C[+("48_[VP>]?,&DZY\0?
MV<O'DGV:74_!_B.S8":WD4IO7J Z'Y9$/49!4]17[=5Y!^TE^S?H/[1'@]K&
M\6.QU^U4MINL"/+P/UV-CEHV[K^(Y HN!R7[)G[76G?M!:6VE:JD.E>-K./?
M/9QG$5V@X,T.3G_>3)*Y')!X^C*\=_9]_9=\'_L^:0HTNW&I>()4Q=:[=QCS
MY/54_P">:?[(//&XL1FO8J0!1110 5\_?MZ?\FK^,O\ >LO_ $LAKZ!KY^_;
MT_Y-7\9?[UE_Z60T ?F+\%?@[J_QT\=0^%=#N[*SOY()+@2Z@[K%M09(RJL<
M_A7T+_P[#^)?_0P^%?\ P(N?_C%<S_P3K_Y.5T__ +!MW_Z *_5RF!^9/_#L
M/XE_]##X5_\  BY_^,4?\.P_B7_T,/A7_P "+G_XQ7Z;447 _,G_ (=A_$O_
M *&'PK_X$7/_ ,8KZE_8Q_9K\2?LYZ7XIMO$6H:7?OJLUO)"=,DD<*$5PV[>
MB_WAC&>AKZ1HH ****0!1110!P/QP^,6D? OX<ZCXKU<><(,16MFK!7NKA@=
MD2GMG!).#A58X.,5^2/C3QWX_P#VH?B3;F\-SKVN7TIAL-+M%/E0*>?+B3.$
M4 9+$] 68GDU]+?\%1?&%Q<>,O!OA592+2UL)-2>,'AI)9#&I(]0(6Q_OGUK
MN/\ @F3\+K"S\%Z[X^N(%DU:^NVTVUD89,-O&JL^WTWNV#_US7WI@8'PQ_X)
M@K-8PW7C[Q3+!<N S:;H:K^[]C,X()['"8]":]%U+_@F;\+KJU*6FJ^);*?'
MRR_:X9!GW4Q<_@17UQ10!^5'[07[!?B[X.Z;<Z]HER/%WAN %YY+>$QW5J@Y
M+219.4'=E)Q@DA1S6M^P7\:/B/H_CZS\':/87GBSPK<,#=V#/\NFQDX-PDC<
M1A<Y*GA^@&X@U^H! 88/(KF? OPS\+?#.TO;;PMH5GHD%[<-=7"VJ;?,D8DD
MD^@R0%Z*.  .* .GHHHI %%%% !1110!\R?\%#/BS_PK/]G75;&VF\O5?$SC
M1X I^81.";AL>GE!DSV,BU^.W-?67_!27XP#XB?'AO#MG/YND^$H38J%.5-T
M^&N&'N"$C/O$:^3>:_0<KH>PPROO+7_+\#AJ2YI!S1S1S1S7KF1[W^Q/X7&M
M_&2?5I%W0Z%ILDXR./-E/E(?J!YE?=U?-'["/AX6?P_\2:ZP^?4M3%O&W?RX
M$ (^F]V_*OI>OXZ\0\<\;Q#6BGI348+Y*[_\F<C]HX;H>QRZ#ZRN_P#+\$@J
M6UMWO+J&"/[\KJB_4G J*ND^'%C_ &AXWTB(C(6;S3_P %OZ5\#A:/UC$4Z*
M^TTOO=CZ&O4]C2G4_E3?W'TC:VZ6=M#!&,1Q($4>P&!4U%%?U4DHJR/PIMMW
M84444Q!1110!\/?\%2O^1,\"?]A"X_\ 1:UC_P#!*W_5?$K_ 'M._P#;FMC_
M (*E?\B9X$_["%Q_Z+6O.?\ @G7\7/!OPMB\>_\ "6>(K+03?-8_9A=L5\W9
MY^['';<OYBGT _2>BO(O^&MO@[_T4+1O^_K?X5#=_MA?!JRA,LGQ TME'40^
M9(W_ 'RJD_I2 ]CK\F?^"@OB2S\1?M*ZO%9R+,-,L[>PE9#D>8JEV&?4&3:?
M0J17T)\;O^"E&B6>E7.G?#.TGU'5)5*+K.H0>5;P9R-Z1-\SL.P8*.F0W(KP
MO]F3]D/Q1\>O%<7B?QA!>V7A%YS=W=]>[EGU1BVYEC)^8ACG=)TY."33 ^X/
MV(?#-SX7_9C\&0W:LDUW%-?[6&/DFF>2,_0HR'\:]VJ*VMH;.WBM[>)(((D$
M<<4:A510,!0!T ':I:0!1110 4444 ?AM\7O^2L^-O\ L.7W_H]Z_;7PK_R+
M&C_]></_ * *_$KXO?\ )6?&W_8<OO\ T>]?MKX5_P"18T?_ *\X?_0!38&I
M1112 **** /C/_@I=\59/#?PZT;P393;+CQ!.9[S:>?LL)4A3Z;I"A_[9L*^
M?_\ @GC\&H?B+\79O$NI0";2?"J)=*CC*O>.2( ?]W:\GLR)ZU4_X*,>(I-9
M_:0N;%G)CTG3+6T1>PW*9C^/[W]!7U?_ ,$X/"\6A_L\C5 @\_6M3N+EI,<E
M4(A4?0&-C_P(T^@'U11112 **** "BBB@#\Y?^"EWP:AT'Q-H_Q%TV 1P:P?
ML&I;1@?:47,4A]WC5@?^N(/4FMO_ ()A_%:3SO$OP\O)BT6S^U]/5C]T@K'.
M@^N8F 'HY[FOHK]MSPK%XK_9G\8HR;IK"*/486Q]UHI%9C_WQO'XU^=7[%OB
M.3PS^TUX'F1]J75T]C(O9EFB>, _\"93^ I] /V*HHHI %%%% '@_P"W%X?G
M\1?LP^,XK92\MK'!>[0,_)%/&[G\$#'\*_/W]AOQ]8?#[]HS0;C5)EM;'4HY
M=,>>0X6-I5_=DGL#(J+GMNS7ZX:EIMKK&G75A?0)=65U$\$\$@RLD; JRD=P
M02/QK\>_VG_V:]:_9[\:3PM#-=^%+R5FTO5-N59#DB*0C@2J.".-V-P&. P/
MV.HK\T/V?O\ @HGK?@'2[30/'EC/XHTJW41PZG X%]$@X ?<=LP Z$E6]2:^
MU?AO^U5\+OBHL4>C>++.&^D'_(/U%OLMQG^Z%? <_P"X6I >M4444 %%%% !
M1110 5\'?\%.OBM+9V'AOX>6<Q078_M;454XW1JQ2!#Z@L)&(/=$-?>-?D'^
MW/XDD\1?M.>+]S9AL3!8Q+G[JI"FX?\ ?9<_C30'JG_!-?X,P^*/&VJ>/M3M
MQ+9Z !;6"R+E6NY%)9_K&GZRJ1R*_2BOGS]@[PK'X7_9E\,.$"SZH\^HSD#&
MYGE95/\ W[2/\J^@Z "BBBD 4444 %%%% !1110 4444 ?D]_P %#O\ DYK5
M_P#KPL__ $4*^Z/V%_\ DU?P/_N7?_I9-7PO_P %#O\ DYK5_P#KPL__ $4*
M^Z/V%_\ DU?P/_N7?_I9-3 ]YHHHI %%%% &#X^_Y$3Q'_V#;G_T4U?B]\#?
M^2V?#_\ [&'3_P#TICK]H?'W_(B>(_\ L&W/_HIJ_%/X1:K9Z'\6/!>I:C<+
M::?9ZW97%Q<2 E8HTG1G<X!.  3P.U4@/W*HKQ?_ (;*^"X_YG_3O^_<W_Q%
M'_#97P7_ .A^T_\ []S?_$5('M%%>+_\-E?!?_H?M/\ ^_<W_P 11_PV5\%_
M^A^T_P#[]S?_ !% 'M%%<SX ^)'AGXI:(^L>%=7AUK38YVMFN( P D4*2IW
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M]V.-,_4L?_9:[^&Z?M<VH1\[_<F_T./.9^SP%5^5OO:1[)1117]('XX%%%%
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M_10K[H_87_Y-7\#_ .Y=_P#I9-7PO_P4._Y.:U?_ *\+/_T4*^Z/V%_^35_
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M.^#KSX>_"OPIX9U"6">^TG38;.:2V),;.B $J2 2..X%=C10 4444@"BBB@
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MA[2*._\ $HW#^(+[_P#L?_MV6NCZ;9>"/B5>F*WMU6'3O$,N6"H.%BN#U '
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M_P#);/A__P!C#I__ *4QU^T/C[_D1/$?_8-N?_135^+OP-_Y+7\/O^QAT_\
M]*8ZI ?N!1114@%%%% !1110 4444 %<A\8O^21^-_\ L!WW_I.]=?7(?&+_
M ))'XW_[ =]_Z3O0!^0O[,?_ "<1\.?^P[:?^C5K]J:_%;]F/_DXCX<_]AVT
M_P#1JU^U--@%%%%(#X5_X**?LV_VK8GXJ>'K7-Y:HL6NP1+DRQ#"I<X'4H,*
MW7Y=IX"$GQ7]A/\ :3_X4[XZ_P"$8UVZ\OP?K\JJ[R-A+*[.%2;T"L $<^FU
MB<)S^IUY:0:A:3VMU#'<VTZ-'+#,H9)$8896!X(()!!]:_'[]KC]GF?]G_XF
M2VMI'(_A;5-USI%PV3A,C? Q/5HRP'7E2AZG 8'O7_!4_P#Y&+X>_P#7K>?^
MAQ5WG_!+O_DE?B[_ +#(_P#1"5\3_%+XW7OQ8\!^ =(U=)9M7\+P7-DVH22;
MOM4#&,PY&,AT"%23G< ISG-?;'_!+O\ Y)7XN_[#(_\ 1"4^@'VC1114@%%%
M% &=XAT*S\4:#J6C:C%Y^GZA;26EQ%_?CD4JP_$$U^)'Q(\#ZO\ !GXF:OX<
MO'D@U/1;S;%<)E"X!#13+Z!E*./J*_<BOE+]N;]EF7XS>'XO%GAFV\SQCI$)
M1[:,?-J%L"6\L>LB$DKZ[F7DE<- >M?LU_&VR^/'PKTOQ#%)&NJQJ+;5;5>#
M#=*!OX[*W#K[,!U!KU.OQ;^ 'QZ\1?LY>/&U;38S/:RXM]4TB=BB7,8)^4_W
M74YVMC*DG@@L#^K_ ,&?CWX.^.V@)J/AC4UDN%0-=:9.0EW:GTDCSTSQN&5/
M8F@#T6BBBD 445\W_M5?MAZ%\"]'NM(T6XM]8\=3(4ALXV#I9$_\M)\=,=1'
MU;CH.: /I"BOS?\ V&/CQ\7_ !/\2E\-)<2>+/#LTC76IRZM(S?V?&S$O*DO
M4,Q) C.58GHO+#](* "BBB@ KY^_;T_Y-7\9?[UE_P"ED-?0-?/W[>G_ ":O
MXR_WK+_TLAH ^)/^"=?_ "<KI_\ V#;O_P! %?JY7Y1_\$Z_^3E=/_[!MW_Z
M *_5RFP"BBBD 4444 %%%% !1110 45\>?M5?MXVGPOOK[PCX'A74/%EM(8;
MR^NHC]FL6'50IQYC_P#CH]6Y%>R_LX?M':!^T-X/BOK*6.S\06T:C4]'9OWE
MO)T+*#RT9/W6]\'!!% 'KU%%% !7X6?$S3[;2?B/XKL;)56SM=6NX857H$69
MPH'M@"OUS_::_:%TC]G[X?W6H33Q2^([N-HM(TTG+S38P'*_\\T)#,>G09RP
MK\I?@S\/-0^-7Q<T+PY&)+B34KT/>S]2D(.^>4GV4,?<X'4TT!^T?@^66;PG
MHDDY)F>Q@9RW7<8U)_6M>FQQK#&J(H5%&%4= !3J0'\\4T$IFD/E/]X_PGUI
MGV>7_GD__?)K^AS[/%_SS3_OD4>1'_SS7_OD5];_ &[_ -._Q_X!S>Q\S^>/
M[/+_ ,\G_P"^31]GE_YY/_WR:_H<\B/_ )YK_P!\BCR(_P#GFO\ WR*/[=_Z
M=_C_ , /8^9_/']GE_YY/_WR:/L\O_/)_P#ODU_0YY$?_/-?^^11Y$?_ #S7
M_OD4?V[_ -._Q_X >Q\S^>/[/+_SR?\ [Y-'V>7_ )Y/_P!\FOZ'/(C_ .>:
M_P#?(H\B/_GFO_?(H_MW_IW^/_ #V/F?SQ_9Y?\ GD__ 'R:/L\O_/)_^^37
M]#GD1_\ /-?^^11Y$?\ SS7_ +Y%']N_]._Q_P" 'L?,_GC^SR_\\G_[Y-?I
M)_P26++X7^(T3*5*WEFW*D=4E']*^^/(C_YYK_WR*<L:Q_=4+]!BN/%YK]:H
MNER6OY_\ J-/E=[CJ***^>-PHHHH **** /AW_@J5_R)O@,?]1"Y[?\ 3-:^
M'/A[\8?&GPI6_7PEX@O-"%\4-R+7;^]V;MF<@]-[?G7[A20QS8$B*X'3< :C
M^Q6__/"+_O@4P/QQ_P"&P/C+_P!#_JOYI_\ $U'-^U;\9M47R/\ A/M=8MP!
M;R[&_ H :_9+[%;_ //"+_O@4Z.VAB;<D2(WJJ@&@#\8;#X7_&+XV:@DPT/Q
M3XGG;I>:B)6C&?\ IM,0H_[ZKZK^ O\ P3;:SOK76?BA>PSI&PD7P_I\A97/
MI/+QQZJG7^]VK[XHH AL[.#3[2"UM8([:U@18HH84")&BC"JJC@    #TJ:B
MBD 4444 %%%% 'X;?%X'_A;/C7C_ )C=[_Z4/7[:^%?^17T?_KSA_P#0!5YK
M.W8DF",D\G*"I:8"T444@"BBB@ JAKFAZ?XFT>[TK5K*#4=-NXS%/:W*!XY$
M/4$'K5^B@#\[?V@/^"<.IZ9<W.L_"Z7^T=/.7;0+R7%Q%W(BD8XD'H&(;W8U
M\Q^'/'_Q0_9TUZ:TT_4-:\'WRONFT^YC9(W([M#(-K?4J?K7[75C>*O"^B^+
M-)EM=;TBPUFU"L1#J%LDZ XZ[7!%.X'YK:%_P4N^*>FPB._T[P[J^!CS9K22
M-S[_ "2!?TJ;6/\ @II\3KZ$QV.C^&]-)_Y:I;32./INE(_2N8_:,\)Z)H?B
M2[BT[1M/T^)7("6MJD8')[*!6%\$/#FDZMXEMXK[2[*\B,@!2XMTD!_ BF!R
MWC;XT_%'X_:A'IVKZUJWB)IGS%I%C&1$S9XVP1 !B.Q()]Z]X^ O_!.OQ/XO
MN;;5?B$[^%M$!#_V:A#7UP/0]1"#ZG+?[(ZU^A'P]\&^'_"/A^T70M"TW15E
MA4N-/M(X YQWV 9KJ:0&)X-\%Z'\/?#EGH/AS38-)TFT7;%;6ZX ]22>68GD
ML222<DUMT44@"BBB@ HHHH X_P"*WPK\/?&;P7>>&/$MI]IL+C#I(A"RV\HS
MMEC;'RN,GV()!!!(/Y:_'K]C+QY\$[VYNHK&7Q+X75B8M8T^(ML3_IM&,F,^
M_*^C5^O5%,#\A/A7^V]\5/A78P:=!JT.OZ5" L=GKD9G\M1_"L@99 ,< ;L#
M' KU*Z_X*A>.I+,I;^$_#\-SC'FR&=U!]=N\?SKWK]LKX<^$X=#74T\,:,FH
MRAC)>+I\0F<\\E]N3^=? /AO2;&?Q1'%+9V\D7F$;&B4KU],4P+?Q0_:$^)7
M[05[!8:YJMSJ$#R#[/HNG1>7 7[8B3EV]"VX^]?2W[)?[!6IR:S8>,?B99?8
MK*U<3V?AV<9EG<'*O<+_  H#SY9Y8C# #(;ZU_9Z\"^&O#O@>POM)\/:5I=[
M,G[VYL[**&1^GWF503^->KT@"BBBD 4444 %%%% &+XQ\&:)\0/#MYH/B+38
M-6TF[7;-:W"Y4]P0>JL#R&!!!&017YU?'K_@G3XF\(W-SJOP\=O$^BDE_P"S
M9&"WUN/[HZ"8#U&&[;3UK]+Z* /Q6\$_&;XH?L_ZE)I^DZQJOAQXGS-I%]$?
M*#9YW02@@$\\X!]Z]PT7_@IO\2K& 1W^A^'-38?\M?(FB<_7;)C\@*_1/Q]X
M.T#Q=H-W'KFAZ;K21PN474+2.<*<'H'!Q7Y5_'3PUI&D>)+B*QTJRLHQ+@);
MVZ1@?@!5 =[K_P#P4R^)NI6[1:=I/A[1R1_KDMY9I!]-\A7\U->):WXQ^*G[
M2WB**UN[O6O&>H;MT5C;QLT46?XEB0!(QZM@<=37HW[./A/1-<\46D6I:-I^
MH1,X!CNK5)5/([,#7ZG>&O#>D>%]+BL]%TJRTBT"@_9["W2"/I_=4 4 ?%?[
M,?\ P3S&@WUGXF^**6]W<Q$2V_AN-A)$C#D&X8?*^/\ GFN5]2PRM?=( 48
MP*6BI **** "BBB@#\GO^"AW/[36K\?\N%G_ .BA7W/^PO\ \FK^!^WR7?\
MZ635[K):PR-N>*-V]64$T](UC4*BA%'0*,"F ZBBBD 4444 8'C[_D1?$?\
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,%4 "KU( HHHI ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arcus Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3898435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3928 Point Eden Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">694-6200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCUS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001724521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rcus-20250806.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="rcus-20250806.htm">rcus-20250806.htm</File>
    <File>rcus-20250806.xsd</File>
    <File>rcus-20250806_lab.xml</File>
    <File>rcus-20250806_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rcus-20250806.htm": {
   "nsprefix": "rcus",
   "nsuri": "http://arcusbio.com/20250806",
   "dts": {
    "inline": {
     "local": [
      "rcus-20250806.htm"
     ]
    },
    "schema": {
     "local": [
      "rcus-20250806.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rcus-20250806_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rcus-20250806_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://arcusbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20250806.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20250806.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001724521-25-000099-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001724521-25-000099-xbrl.zip
M4$L#!!0    ( #J!!EM#P]U\0R$  #U; 0 7    83(P,C5Q,CAK97AH:6)I
M=#DY,2YH=&WM76MWVS;2_O[^"KQIMK7/2JI(R?(MS3F.[:3>)G'63C=G]\L>
MB(0DU"3!\F)'_?4[,P IZF9+OHF2V0]N;)(@@+D_,QB^&22^]_;-0'#W[?^]
M^?]ZG9TH)_5%D# G$CP1+DMC&?39-U?$5ZQ>-W<=JW 8R?X@87;3WF'?5'0E
MK[F^GLC$$V^S<=[\K']_\S.]Y$U7N<.W;UQYS:3[RROI[.ZZPA96;]=IM5M[
M>UW7[G:$:'=VG>:^TVG^UWH%C\+M^IDX&7KBEU>^#.H#@>\_:.^$R>&-=)/!
M@=5L_NW5^'T\ZL.MB0H/.F$"UWHJ2& .$8RI_ZF'GG[!V(.'B?B>U+DG^\$!
MK=J,E-WM*$]%!S\TZ;]#O%+O<5]ZPX.?CN&I;B1_JL4\B.NQB&1/WQ#+O\2!
M9<'@].N-7LTN/._)0&2KLVQ<TNGW@>S*A.WO-ZSQB=^V5NGW&?<2V&2_;[>:
MS7:[:=O_;?+&'V'_%8LC9]X5/5ZVO_OA]T,S=E<EB?(/<,>O191(AWMF5VB#
M].6,&.U6^'TF[4;S;#7#);;RJ_1%S#Z+&W:A?![ ED[N9G.AW3R*G#1F[Z2*
M'2D"!\:\$*&*DIA="D<%;OV?*8\2$6G6?B\#'CB2>W!7G'IP%P]<]B52UQ)$
M@G'V188"7\)^#UT0F$7H8]GC//5'&B>R-US!5J1]>/6//UB=YF&G1@M>9/[[
M,'C(71<40]T3O>2@U9FY(/TG&;B@!P[JUMX349L&.Y )O-L96W1[YJ)__&'/
MMCN'V4)7/)_QC;3:C1W<I2^G1[_5K1JRUX#'@K5@AJD[9.*:>RE/4",[/ 9^
MDST>L+_#+UWU%P_@@NPR&3#I^VF@DH&(>#AD6V?GVW7Q/809(\.[S'$NCH]K
MQ,GB7^<?_W5:A]^;]NA]5O?'']J[A]EKXU %L8K@R>Z0'<5)Q/\C N'PN?.Y
M5EX$/*!\V<?I]&04)W62$E\D/$[@1B>;Q8!?"]85 F8=R$2BT9G+A _BNAF*
M_[&&7A4#67:Y&!KF,YNA3WC"62]2/CNZ.*[;S84Y^>Q\FG.9*WQ@2&!#=%"2
M 4]8('CD#8&7O!Y3/1;">$"C&/[@ E.#6@<6].'F2! O"Y8H>%# %;\+&CZ1
M*B!QH,$F+]SPF-T(SX.'/*%?6G'HIG'H)]!OS.=)"O\#=N0UX#['2_%&]N7]
M98WU5*0Y8\2NP(6YDG74@)P(X%G#XAQ&0MYUB$L5Z#@6 O\!9>!WN T'ZW'/
MPZ$]3]UH]>I/S&/6>R?$1+\:9.![PH8@"!5S;AISGH._#9S"XC2ZAD#+8UOG
ME]N&/5"I(G]HRVVSTY,/I_4/8&0CL+%DOVM%;>LJ_YH',!>?=X&1_I)^5T0B
M^]49@&K-6!IXM(_C* DL"Q0,\,4?SK:!^T 91W&-W4B8U!A?&_5)OO-I&JE0
M +]>*G"UDR&Q\B?A8N# S@/<W3YX)Z>7G\ZW(:0,^C *"="YDRB8U5QFF^L[
M5SRZ.A[5<94TIC)4L43CJ54?=Z^199@$!=E+\7(6-=W(9,!>[]N[.@J!B7MH
M<H$)0-\-:O23B3]3Y'JRZ&BE(1:Y C^RZPD6"R>-X$T8BR7L3Q.ZB6"^#UG&
M0.S7HW]_.[HXJ3'$"WH-AO2VK$.V]>[WR[//IY>7[-O9Q>EV]O>GXX-;(R<V
M%3K7V%G@--C6YW]?GO[XP\[>X<7Q[Y?;&$<X\#@!!.#L]T6-]3W5!:GO2A4.
M>.1S1Z0$(*"C%?( =0.,#=P"Q'?%M?!42-I*]GJ@G@(=%X!Q](#>GM!L4/31
MM,Y"-D ED_M_Q%Y:7=6 $5T^!!<0HWT8K)>']I$)[3-3&Q,04.0FN/T?:2 T
MD[::.E;6$52HL0#T,W.N3@D+P+4@QX_O!?#V-6K3/DT<WEY8E!,IT( ^3$:&
M'CFAX&)DZK8QW^N<CU<] TO?$F8W#[\)'> %ZJ9@)4:62X%E8Q88BYQDB0$>
M#>EF.EM I\*5T .N+'I$8)@&TAF )@+CY$E@IV+(0"0.54)<Y1'1"X-I1PUO
MZ0*5P!+4'8\#47X]>U^W.1"/L#AXAI[SP-UB#BH\C&5IS2"V,9<N^RJB: B;
M"$NN@7%NG#1 FPVDZ(%3"/1.),Q*]7H22(LA"\F6EGR];>@^PCOZ* 8<P5.]
M(W$HD-<P=,>'40[)4JLTR@2'\%L8LK"J*<ZB."H6"?H$<='7Q7&,L&;8@T8C
M@#"X7<9QG8C+S$@:'!N'$(H(P_@8LV$!,U2-;O%X@A*(Y@!\9"!Q9$(RW(H"
M$M%@[!O^B3/T5V B,'^R./% B(2FE2D8+7ZX1S5D$-QFLEAH9,)0VZM>BNJE
MP!2#2*7]P<@ASP :S6>P8(U@N"(&H=-CB"""*3/42BZ$IA1=@B5$%@#*<U Z
MW%4IS"T&12.=*[PG1KL92S!L#<-+BYJQY[=9.?#Y*_S1PPLQF8"%M-1^*0RO
MGH(+VEZSU0&0741XUZNWQR/J;TW*_O;Z+!'HE$EQI/H1]XE&:XCRKA;3?5X$
M%VQB/&'29F!ALZ#4> ))7<QGJ$C]$%(O":&C(8"P.#+N'[Q\$E:O+8*KH_,Y
MY4HBL]2_G-0M>O?QUX]']3;XW. S.!*<!;J.&=C:!"J_97T$KWTV0W$O5E-<
MQ;ZBFTPK0W2T:/?B-$0'.[L;K37X(B.$HL7P,@&N<>[#)!/6;YT4[(5PT.$B
MB/N+=G%IV?&:J=K)9/0:R)]% GA&G.9-X&$&A=5,.NX-WYEF&(\?)^4"_,5H
M LN%0<&'\,!Y!09&UM8PV)$/0SH%! SF<6RBP0("=G1Y?+[-CH(@A3]_ H<5
MUGB+YBZ6/F0XRT$DP%>&F&)N,83)WC='C_!NK+PTF?_(<O43^N<@&L%M?5'O
M@IM[5><]\.(/N'?#A_&KE95R3(G9[FS\IQQF;G^W:9=$S-JTY4>:IQ-X1Z;1
M2>(@EH4XEFV=')_7V"<>04!DM35" D:%PGF*2"<"^K^/R6 \H 1(,5>G#.B=
MY^PH>-\ZO[C8QO>W.W]#R1N)ZD!A3.4,:!C@*^FG/MYHV2"PXBIF6\D-F"<0
MQY@&T%F7>AIJ'(=[OHHA'$-T,AO31&M@UU(?HCXPWZF#HK.P?:K8[;'8C;@+
M_W -NICY_ \52:U0<VI%PN<RT!BB08HJ0CT]H< 51 P%W+= @:WD =S22SV2
M7X^'A.,FZCOX>28%1&0%472C%+$GG7<?3[GKO#WB,O51TCWF/;2A8:1ZTC.I
M WAE3G]7QJ ]0)^D^$JP=X,"+.RFPF0B(+@2X&'C(_<,CRK^6(X_9)SEJ.%?
MA=B&L'8.\AV)/LP@J&7((/TQ!P*!LRA\T##D6#R]5H'"%X\'J)XH4KC0\-^Z
M!0EKRX7OT;"C3Z)!RLERCZFX(:OGF!V*%Y,1DTX(ZJX0P3:(!;0Q(E6$*'P6
MGFN'@WW][>Q^!JHB_3*D!ZIW[J+Z;>FD3'DAT>3,6#. B2_$-T:_61]IL-E)
ME'B-E-IM"/I)L=)DZ[T#PV(*7TO!U[,/9U]S/&I;;_I_BL4H6T5I,;>MS\:\
M+&U?(DA(UZ* KNTBH.HDB$TZD>RB()Y?/D+-%''J6-D4U2),%$ZE(<@U^W &
M#J<(E -1L0Q@F7$!I.>.(T(J1,"*A0)P.%Y$=?GI?%9Q5(7L/ST;?<V2U+G3
MF7%0EKQ%TMW!'5F-7,YT0$M%5:5CB:'+KT<7==NVEF$\;:DF. \TYD<+88PZ
M!%187/&1I0%REZ,KIF#&!4!S'I\V\O,N.F*3L<G=4U4K!D]U-Y+7Z+,C^V?[
M,E;S"I-!T[LAYNR?J? ]Z<"6P\ZQK=C'+<YJ=]CQR6YKE"!^=!ZV'SCYA2UG
MI2SNJRS.HW  'MY)E/;9">7#1J<'^A&G3$%W2!K@]\9E@[U72B<#Z8DC%Q%+
M*E#"A[;>GQQM(U[QYQC7Y>A)#JH2_A7084U,3U"E6&4:GB&_?W%V^6D\P:_U
M(Q!DG&8:ULH*VOK"=R0H8HG%A.W=PX!WZR%W//C;=^%EF?\[[II[I*K "HA4
MH[H>4^LU F"H, G-BZE-JNFIZ;_KP[_*#SU!G%C4YL1Z QF-2B-AM;H2DDJH
M<!BXS;(Q/DX&,5[6UFV4#%Z<.<MM#DZ3*/5Q=T&R(5;!;8Z1&D<V)Y(=V5WP
M$M## YF%>WA?H7Q7BOC)1?,L,%FHC#.!L_N\GTD@,C%H5\0<>40ECR%X9I*.
MN>>%P$4P:'^Z=$<4B4^" 4(Q?< 1UR](#+5B9EO^\<7Q-@2!^X=X-GM 185F
M0E3;O7L(+Q?"[7+GJI *FZY8Y8299O:"4\YJ,/+50EWL-3DW>'N-=;F!I;#4
M4Y?$]E%W1%+I2OJ:*?1&X_0!8G;$XB'\T.4=@4I8F(*6$E.U312VH*.(*1MX
MF.!<+)LVE#!C12))(U2(6!L->E*8\WACFPJ_ZXK8#=$6=#SQ!!,4H.*'ZZ,$
MUK8H1+,P!MNQH$0R"K<@O:"K]D56EI\)2YQ'9G0*%$,9&!G#;OP;"+]T*0VE
MLKH-C0?V/.[[YA "4$]@5DF_7)O.>'2HE$[H%8NT02VX-*HN&$:+2F DS2R/
M'#FC8",_*,!<&6F;S/M<!IBT#F9-9(UDY]7;Z48+J,QT2P96;,E006B/K;=F
M6M%C.GZ%/]GIQ/&K3Z/C5Y>CXU<K.I1$M5C3!\@X.9^SSNS0@:-(&[/7^_OV
MK.=.P'%#G(6U+'JLW:""1]#MX%V#M7)AT29_B? ]!')D<R5P'RPNRS7CY306
MIOALD)W2&--#16W G41>Z\V$&:*I][# H1>+)(L< _@GJ"L'C+'Q4G!$,C0W
M0 ?P$/ !0;.#U[T7W0A$9ZBAQ"S1CN0V7L/KG2;+ENY&_(:YZB;0X]'(('0^
M\Q3HEQYWI(<9_*)-;[!OHR,V>/^RA_;P4!9HJ@&\CIPS?LVE1_>8]]$]F2*,
MTZQ<-#^DD5?2QODA#5QBEJ8)Y;5*2/=K_'T*L*M-1&M\[.!'=L!#'X_)4M#S
M]6I5F?=(E7F5JEY"55\@'INN6@6#%AU7I7-.4\[0PJW].4]B&4BF8(."(I:!
M4<3PUTBO7M>A$R2-RA++$OU4"QX(=.(,ZFF(+\MN!Z7\VFJW<NVGI91*E4#[
MZJYGO51GBL>/U8W%*:,8Z:=8CR&R" ?OG0AQR&!H;W/*2<2I.:H?P,:S#T='
M7XHS[8KD!E-&KVU0X[FI@E>_MENC/V3;1B>LL1%$%@$7=9BNI9FQ.1M8B5 ^
M02U8_I,"5VU=_/A#:^_P9)N= CL L\2K.N)M9'FN1-XIRY:ULZ0PHT^3"S2*
MI=W.61J%>LJORFYVV?&G8WA[C"'7MRSQ9.X 9T1XXIKD,;]MS$>8B60VV#EZ
M(S<R%K7\X+9Y&%>"3@X*N3G+G8>.M&\0@254KC::80%41:+#4U&"FJC@Z]%Y
M4@TGZ_.SNLZ-1O0PD!OS K%13%284)8W-!//7TVY8J&YR>!:F&I&EY&BQ9$"
MI=9)9CVSW=%:0;%F*?.)!8Q\I@;[K((ZN8!QHIRKNL:;D$E@+CP'E7%>2-[7
M>U,*; $N:TX_-(N_WL\<,1[YPWA;AG?E^M=E?3HN'0GI=],H%CYYL<B;K=9$
MO(!*N#UN^6I4LBYP@P2BZSC#>$!S-PLWOCLU!RB>:\:TJ]8$HSMAS[.-\/D0
M>"QUDA0A@T*4D4B?SF[W1BP+6B %'SK1D8KAO<#ED5M7/2!/)$QQ+#5B0$C/
M&1#;:#\<YA7IPGN"2"7L/8@6V<GBGDQ:L:G9PP1=0EIT-P,!(;X.3<A0@33!
MRXIT1NG1S)T94[/$L51XACL6V36#//,@#5-P>.J-X^FRRKH]N77[( +"V9#7
MBNE,\#&V/A!?')7%OMG[]] YK05USAA2,&' "OYI?@LU-R@H1X(G04FI(!"9
MZ1D]J/7_/,U:FXD<C,Q1)EJYHC.2F"V;Y@+O=49=%O"R0>Z/, N PK:TCM^]
MMSNQV*97TOW4TOU9>VD*]G[K(QC'[95),/(3)<OLPWMR%6>O]T>1'_J?'IK[
MAS+8:OIP''6Q$&VJ-=-=$S:@$W#WX3B"4XKN0=--FF5\GZY2C]!*2J@P.VR4
ME=><!:1FP=S% QGJ:Z O8+.B8<&A4]@B;W26$-7Z8!A+1_( ?H5 Q."Q-RKR
MW,P)E=J90H36(,P3\(.N_,#AJ,X ICC>J,C'!GNPH7&>':)C5.#=83DLD(,:
M#DA,8=%6F:25GA]/!H@$&G\Q=8<XB4#!!&KFF:&I^RMNF4EQ4:.G\50U"-M
M>.&,760>.@:>"OJXH^]Q,[*206NGEAT((R)2%P+=0<X=M3"::J.5KUL&!*:,
MI<=SOYBJ=.)"PZ-Q-!ABHULKU6&S\2'<&ZGG.]8I%M=7+-&L31[[R/HO(&OI
MVLNI%HNX]P&85YWTH^927DK'"'0;LR(\S>_L2P4<S\THA3(@3OJQ 'S7LBSC
MO))&TU=MJM0,(RSJ62H#N,/D'_ELG61*'$;$F)>)!;'QR#>ZEK$$!KZY:7 <
M#%BP ?N]D#8NBRH[N2/;,%Y*'MW2'TZ3+1"2 GWCDP6P_Z-<-U8<23RPS$/L
M2X?%(CKBQ[YW?83\%*@HGB8#?7R62DG@(J:IM#+%@-4DBF24';G,VXUQ9YCU
M<TMT%3M,E7<]&0^P+<AQ@36+,"DHMW<[^WLZ-'BWU[1T=AT[B]RQVM'2\(VK
M75[9?8""IWY<1!76VQ6@<B[*8#8S&UD@"J@MJUDGL'M&ASBS&]B5)JMSHM H
MZT>*:!YVH^DI\ 0;['?*>R;ZO&IAL+QT2743?<(<2YSJ(+(R(5 'Y9GZ^87T
M;OI("&$?J,'!9E-J=*K<!&)"2C,4LLGC:\#L:V-&,5:$-]8+ODTR@,!L2I3@
M15@%.M;>[Z\Y1ZPRL=NNC2,M6[-.:\VP'VQKW%QLZSAX@B:<G!N>F?K/X%A0
MFAV(:YG2 J)TRX"XE'3-\^5YV0M"0C<J]UP(ERT6Y4Q>S&MC4#NX,B9\=+%"
MU-7(,QC5&T3J/BIUA52[A!TV(.0ZF;ZONA11$)2J#3H>T$>O%.E"2_3,$N-\
MB<#QV.IZM.11I:8^M<^H%8<N$@)64 Z"_1FDJ%-VYC7 *]B< !OTZ&Z:<UX)
MP_4\!#TR,4PCC!1T:4-/"Y^&.(V_"S(-&P,Q"'GE:.9T4:0I7=119 ][GT9=
M.MVET),Q3]+),W"B$<0M%-!\E)GLL@N!OA0[<LCCM_;W=PHR#)XX*'NT4)D"
M2I1VF L+DG@2H:';C^:5I7^FX)CG92 CT#C+<Q9.-NDUTU^*1],,<6[925!"
MR@-5>!5@)0D.D@;ZWZ#MKF+S%W =D3ZZ;S.6<>C<A8_*&/<0D6L(GW1<@;"W
MP]&&DRK,EX/H-JBYJAKCD:LQRJ(^C(S7$(NAV(),=I1UY='\A@D&BNS'\?ZL
MA%O%E!?,SN(3CWER=!3G-C7TOLB$CDH]U[ A1E@P^TB"( K=\X[,DP88"*W0
MMDN+*NJ><7'5I]&-0,2Q<N2HY7%(UADBP2BK,,6@W=>RJ/U2G&@_Y72H2)CY
M%64XKY>"<3P>Z7ISJD8+\N,<L$@PD+2CO8FN*+@^+9 8E,<RTD5;$I0<>,F4
MY\&O7(S)XCS?0[\;MT8Z&+D+&MT%(1S2*-G!$%1$M*O480FCW8F W62[YH^$
MZRL$ 50E%P/SC(Z[Q&GW#YH]AJQCZ3%,T$$T[@W-<0"<A$[;(6$GIC)C29,T
MQ+D4[(/1^>/.T"B!J@=T!CSHBWPIA*4GDM(G'O!![/"0V'5BXS-OTAPJ,+H=
M_##"N@JJ=CC-:>.86;;NL1PP8F/CRP>C,D>18\D>[)_Q5ZEPAHY>$]H6Z;J4
M8;8^T^@:Q\H$+6^?;=(/65?L?*W4H"O2[18U/BL=T\^=84N@PN[3$;N"<<79
MGG[7>PS1D>]+:M378/]6J7:H(6K4WRM &<,B( ^V!B4@1;[RI-8^P1U:(ZNV
MB4/0YW"[[FLY:I=F6J=-^D69EX\MC#PN,3B L%5!D&,\ F6J/!-^98J4=(_Y
MFF9<PV?H%X&C(9CNJ#_72(_<(WU 9-)+@XA&A+DG Z8 1X^PHM-\!,SC-VL%
MPF LHG<XX/IP"H-H01'E(3)T!5:GQCG'S?C& ;H]6BD6[@?_4&EJ:#QAE/=G
MX/%@S_[RQAAGI+&!9<X"I*O60XM5UG=6D1+[(CD[Y3!GIK,^TS_1R_G7%R1B
MOK8+\O;0[Z8$- 12! ,,\=:MCK6[S=H[^W6[V>P47:19*]OIM!SK2<ZOW')L
M")3(-=*ETSXLXI_E92K\N@]?%X[Z%?T"]IORKL1PQ#O'*@H5M9H\ZO6XC&+-
M*SO-;;9OVW7+[NR7DE<&5[20NYEED4\EK9HTG\#[Y3Y[!RX+,-*<)3QG/A*_
MS9,S!OH/*?I$I%I6/[NM'0NXL]WLU/=V[.:"\UD)D_I=3='%55JI@WAWX>]8
MMU^M7^#OT(G$ISQ-.B>;@5^18N_.SB^/STX_'Y]>@@OV^7@A5ZI5CA4<8[/_
M[+QH ;P%\W*>'UA:H_5LI0%/700O%NI?4))9LZVS(*OR02! !S68<Z=J7,9]
ME0)5%EJ2I;]5;LZO94HF L56I[ ^C,5!]H]#B.(@>AP>R( F10_=ZR/JS6:C
MJ24] 3E.W.S-YG*#+OV<N-/7VNU&:Z<]]W*S8<V]=MNPEMUH[LU_]+9A;[\&
MQJN:['I-=F>A87\FSM7<"P(2ASSXY57KU<@&4JWA09-9)&#9>/FM^U.WVN%W
MO'E:PTP*E):E1]0[>PNIG:^4C/VDJ /.*>8ZT0K3F=E6LY8KF\F%;O2>7,KO
MB^W(0]EE=*O1SJB\FPT;]"TCD\QPF8?KLF]8N[H QRRTUA>T9^W'D++-VY:*
ME1[*2G>H)VS;U*?"WKJ9G.,(T>O=MF"LLI]R!57XB&O=QPK^!6"$[!SY.&IW
M"XGGK?;1>.BN[7S(&-4D5S?)I<6H1_]-BA'#_^\U6KMEE:B/YNC_9*<7&.]:
M8IV .>,_*6S+[$.3+:A4'EV'+KH+KQ^TO.*RJ+"R-.NR=DSSH(>L+V/C)=:Y
ME(Q.O')2SBM.6P=.L_<J1JL8[3E4VFZETBI.>Q9.Z[16QVF/%,:5WO_4+6'&
MZP[GN)SY-MC+;<-,"2H7JRUK/&\A]E.IM$6CL<TCCF55U"DQ=3H5=<I+'7N%
MLO.8$(Y59AOZU320U=CHO<RF6?K"D/@:L%[>[7-9]VV9O, JHXB72MBL\V-%
MU\VBJ[5W3PRI(FS9"=LN*6&-BS!1R6L.)JP@3U6-L49C/))_64Z?TA0!8T<#
MTP_S_CGW1=5B-49YQG@I^./%G$^=O"#PT5K:H:X@E&>%'W<J\I27/':G@H?+
M3!Y[V=BCI ADF8UHL:\Z'^NK_A P<MTX[9ZPU)H"%&M&G=8]P>"*.L]!G9W=
MBCKEI4YGA157+R4./?-#CE_2UKVXL&=/W=-]A.-8)/=+ZJVGQS;VX83*J:Y(
M5)&H(M$FDLA>UB4M:62Z!K4Q:BJ;457)9%4R5=)],PG;7A8VK@B[%H1M697$
M;B9AF\N6,K_4,ID-/7->3;)DI_?+Z=)^I"]!XL<#U'2GOLU'([?VMBN8N)2$
ML9J=BC0E)4VK69&FI*2Q[960IFQ.737&&HVQT0X6?CE^A!AFGQ0WR.%V50?]
MDL9X,?EG[&DHXJ3XK3MB_!I^??X%I9^M%69EJIS9W;7J%77*2YU5GO:OJ'-W
MI?IFY)O7PHP:;_$EX7*K"6,KA.%I2H$J$CVG[+0JV2DG8:Q58G./$G6N07E6
M, -P>7#<N4FE ??L#UB:BH]'=+HWB:SWC68KNI:<KI6\;B1=[7N>Q%^/ JU'
MA-*?KJRHFN1&3'*COU)T9C*&GHKC;=85/16)+(V8\._W/'RPGJ!C=0ZI]"3:
MVE\"?:@H\ZSH@[4$J%J1YEF%9G<EE"F;IU>-L49CO 2O"QRL!R7?UE,=56Y6
M1:**1!6)*A)5#E@U1FG'V&@'[+-(\F)Y@KZ>#";?I&\B+KWV#=7-ZY+[JIAX
MLYGX/FAHQ;L5[Y9AT??"BROFK9BW#(N^#Z+^D@LK6K D5Z5=3Y2V&*":XK--
M\65%EBP4(),#'HG[G\9>AV/VU1A/TG:@],?(WO%8.@\Y>+!)/LZLY977C=F4
MTU85MZT#MVU9C>9:G[NLV&Q=V&R_8K.RD*-BL\=FLY?2YN=$>FDBW(<DSC=)
M/&8MK[SBL?+:AV="<BMN*\.ZEG0M*S:KV.P9;'[%9A6;K1>;E2V%5(VQ1F-L
M=%KG$A,X,4MCX;)$P?K\$((3[/M297NJ,5YXMB=?\.8UU;*:G<:RG4++!REN
M,('VK8H^9::/U;0;R[:.*C&!'O;=@'*19F^OT1FCR0M'EA>2PO4\BH9F[)X-
MH4H$7VPP@>YAQBKZE-R,E9A #PO+RT6:V6;LYX1W/0'_=^7UVS?P8P+4:N/@
MH8HE?I/P(!(>3^2U.+R1;C(XL)HX</$IO;J#YN@1WHT5FI&YC_@\ZLN RF([
M1 4]Q2Y.SLR6YE;\B8]+]Y=7TMG==84MK-ZNTVJW]O:ZKMWM"-'N[#K-?:?3
M_._NJ^R908[7A;POZMU(\*LZ[R4B.N#>#1_&$].".17WX'&F/_M!1 Z+C.,(
M[#G_B#QB61,LLCL;O1&><,#BLV,54-4]QU_><8\'CF"7 R$2=L(3/KZRV6MJ
ME6-)6VG 4U?".K;7:-9LZRQ@,*2''P)=:.*:]TB81[)(]>8P78^'L3C(_G'H
MRCCT^/! !O1F>NC0C&4$&#E^T@?%;=&71\+0:&J!,-ZP>;.YW*!+$_I?7]NU
M&ONM^9>;#6ONM=N&M>Q&<V_^H[<->_NU=K/S-)-M+33L'1''$G;L%G.EF?W)
M[=7>0A+PCS00K-6LH2*UF_;. @CQX^S"K:F[@NP]I998;(M.A"/\KHA8RZHQ
MV*-VMD>/-8V=AKW 1&9X!ZB0ZG9C;UJ)='DL< !4<=:$8MO\[,@QCP<UYL!/
M)OY,Y37W@'-B^CX;J-\K8=2W<-((=G2ZJ>A=FU"=EUSO\Y+[]F[5::%BX#5F
MX'V[I R\T5^WU9]<X7$LDOLUHE[3G$FMN;LL6EOBG,DF$LC:6?;;J^4[ 5!F
MF?<D[TIOIK.XP2CSSBJ_>UDE >XB3Z>SPAS:"S#T<:*<JX'RP&.*Z0#)[B'%
MD\GP!1G_G?9^9?K+2Y[VW@H]L]LS6_/A_C_2.)&]X1,B>7=^DO(Y7YSM=1T5
MW('=:73VD#U/8*AKX;)>I'R6# 0S"136DP$/'$D:B"?")_"JIR*Z:2AXQ$3@
MPGT9,*D9($,G:U@![*5X@PSHD6/E _</?XK941"D,.R%"%64,!6P]RKRF=6L
M_P8O]>")&YD,Z)G+'!PCV.STNS/@09_&\F4<2W@6'Q?=*.714,_ WJ$9[#3F
M)E)*G>S\N:O<(?QOD/C>V_\!4$L#!!0    ( #J!!EO+MV*^\ X   =N   1
M    <F-U<RTR,#(U,#@P-BYH=&WM'6U[VCCR^_X*'7MW39X'&[\1P$FX)TOI
M+KLMR1/2Z]Y]V4?8(NAJ;%:R$[A??S.R38! 8G(-+VW[I=B2I9G1S&C>I)S]
M8S(*R!T3DD?A^1M3-]X0%GJ1S\/;\S<7O5:G\^8?S1_._J)IO_]T_9Z\C;QD
MQ,*8M 2C,?/)/8^')!XR\BD2G_D=)5<!C0>1&&E:^EDK&D\%OQW&Q#*L:MXM
M;Q6N71\XMFUX6J/F&)KC]ZM:WZ[:FGTRJ%?K=K5FUZOE6_?$Z1O,]@=:M>_4
M-&= #:WNV%6MWF?4JE59 [J6?==D7GU0I?U!WZ&.67,:MF$UX$7=<RRK5C/4
MO,,8< :\0^E.^B+@YZ5A'(_=2N7^_E['-WHD;BN68=@5'LJ8AAXKY?WE8N][
M.^]K5G[_\+[G#=F(:LM?\4F\>@X>!CQD2-E*+&@HD7 TAJ6 $2U#,RS-M.8&
MT23S%@:"9_TVNGMR'+.J&77--K-Q5H%O-AJ-R@3)DD\&PWU^@BS8W*=R#L%U
MG4U[#KB\N\\>J*CZYGA  V+NS,C]"(X%B+%5=74#"OQ:8J'VL5=JG@T9]9MG
M(Q93@I]J[,^$WYV76E$8 ^]J-],Q0.ZE3^>EF$WBBD*^TOSAAQ_.8AX'K"F\
M1&K(LD;=.#FKI"_/*NG0_<B?-L]\?D=D/ W8><GG<AS0J1M&(0, ^,3%CDRD
M/[GOLU#]A/8N")#@7CK_)+YF@_.2I\'RA'2$(S'N7H"(^2AF[P)Z6R+</R\-
M-,LL-0<TD.RLLC#0!N.V0T!CVH*!!0TZH<\FO['I;'RKU#2 CVN64[7,1Y-4
M%A$1;, $: HF5] ?U\652A8 #*+6R8V!ZN<ER4?C /E&O1L*A'*!U/I$^K 0
M:KZ'2;(Y990(]:3DULU050@@JOE[IO#,G[B/SP/.!%$PL94BU.K\MHC_\L?-
M_-7BZ&,@3^3G3R#W(GX+FK&)^*#@(?,LM\W ]-=TS5ORYWR2R@+>.9%F5*G,
M\5T%N#-E4:0.?TXQ_H'4>_@F8^L1#[4A0^WM.M5Q?'K/_7CHFH;QM])B/RIN
MH6L<C=V3<0QM<DR!3_H"%S+]G8[]>(;E+V/:#UC>VH\$(*-Y41#0L61N_N,T
ME[=4MVCJH]-LK'X4Q]'(17AA8XNY1P.-!OPV=)%H6?,#*KJ1HA,#T6(_GSEK
MUJ&I\OA]HZXWC-5-AFZJ]Q4UGL@;,RK:*8X^2&F =#DOV:4E9#/PH2?QHP2)
M\2- >#JF/F[*KD%,&".?H*(P?Y:NIPKSE @>\"\3V1KEW0&<2+@X$<XU /[2
M!G3$@ZG[YH:/0,B[[)Y<1R,:OBE+8,9!VD?R_S+7K,,$ZO$^1;(&0ZAER9 V
M+23PQV[GIOV6]&XN;MJ]1:Y8#;>]'W#WVJV/UYV;3KM'+KIO2?OWUB\7W9_;
MI'7YX4.GU^M<=O<"&:,0,I\N>K]TNC_?7';+Y*W>TL$HJSJ-M0AL%6)G)<1_
MO/!?D479$\EX=WG]@13?Q7,;/#5CTLT;M'==^^WQIOU]77<H;* WKMO=&W+=
MOKJ\OCD@P*\2(1,*7EX<D1[ST)$@IDTB0<SJD7],HH%R^: I$3SF,&=[X@W!
M!&3DPHNQV6S8S@$AC,86@GW-QI&(R5'^S"B86TS&A-VATRM4,_./W1>(ZY6R
MX=JI95<BJ8L&EMDD=GUXHXU@B"%^IOETJDUA:HV%,^.\U+Q(;A,9__U'\\0X
M/2DK;[JPO.]R(_KZQ-]R"C'5IG[9-;OE$MWWN LM^<K;L/+H()&?>"0]KKRA
M,NF$GKZ/JU_3JX5H<]2>4- 42()4[G+4"96D-V8>NEP^X2'IQ)*TAN Y,7'\
M#>]G6_>,&@V][M0W=8QL4Z];]2<=H^+O'>-DHR\.#BC;*N)"KO,7<X_0&D_0
M)WPLU\N+G*[O]G?7314A*+=(P$ZK(IB]&#;'5I2$L9BV(G]QY\2 *,958C86
MT1V.\[!E.K"MLX#>4_$X8I;+7.P_1]R9N_V-K<$['C#HW =5FM&SBN$Q4[/K
MCMGX3M"-"7I#)YTLEN@IQEZD[DFIZ=2 N W,:CQ)WI=KA8 -'BO^:+PVE&?H
M-6M?[ 6E!M #N03/0Y!?P?&0/E>N29$==(]0 7-G0<$M634[$*&4![:^I*UH
M-.(2$X\$M0U)!>)X*[KDD$6A<]TC[=$XB*9,'!CO+VI THWT5=R_.G1N5I^(
MG6_($;OM]JW:=1>^+YB4V7_O83PSW_YJI:;=L.KD*N+@ [:!3<@G.GU],V/O
M5GB58IJM[ZX\WB^Z_"WX>2ENHON9I5XO-7^A4S#4_>4%+V\09UN81)D+E^(*
MO *N"C$*.@V-4K,%5(7>(:=/!UCVE0F_5K5Q%<&:!?_FX]0+S/(>1JG9<*K.
M:YG,>V4P983 @-F5 +;F8QJ0]H1Y2<SO&+D<P,;*Y"L84#MBT!V1&5B,((\=
M/^:AO4BW%Y.RAY#JWW^L6V;M5)(;%K#Q, IS4UN%D8,$%X5<"$85UFZ.]9;C
MI^35YUVSW,75$>Y<2*<%!626FE736%8_Q]\8%8L3\7T$ GZ%7+@8 #&M4O.D
MX6@GEO&(FD6\G,:>N#A'[\#28()T56I#D.PQT]UEP@>8S@AOF4]Z:)J0]U3&
M6>)Q?8)CE_IE^_D.TYH5D6T1H]:0>9]58IN.P3(<"XXAIWXT(7T61/>X<MB(
M"TKJVF]DP /4G%P2CI6D/JQH'!')1TD0TY!%B0RF1(*G*P=3]67V0=2'A4L=
MX"R1+A[27PF,(P@-IWG;( I@<OP.K56.X1+IDGW-&CU33[<N26+I)[7-$C1K
M*_-.=,-ZK;3*^JA105;]! /CX!*8E(92>R&G%M>VGP2/@3<QU):$6=A%+A8?
M#/B$^9JJ+)[I8KO4C/X/Y_LU2/>EI#RC"( _3Q(RGBMYN4Y 8ARKF@GC4JD+
M5K@<F372>G=-+-O0H>,*2W&CRL_]"#/L-R?WHH![L +A[0=0RZ";@^?9V/EZ
MV?B!'&24T>,Q#YL.!;MJCHT7RK1F3.R 9E0]O_/QZ_/QE6"HC;&.1Q5QHN$@
MP'5'2_@Y?JY^O?P,9-&\.;H\JY]-Q]>LH_YQ,>Y.^W[G[ZWS=T?*A(F-N/SD
M.Y<_<+G--.?(*\;E6=\7QJU6AN2V'[>:L[12MX@)<*S&JRJ2E?AG;A(0P]U7
MI^AEI72XHC5GSZK6S"JPV69#O3Y0BE)/NX^OGY#;;L*]H##=X*G5M)#=&Q(O
MH%)NL=KDL$DG*.*U)P46197G=-2/@B.YS9JB@U[E;E: KN2#Y3LK;"[W0PYO
M'G:@]64JSQSGS+96(L%A\Q>/<NXH$?;E7?-TRYZ:5E\IG)DE5RLUT18$<O;B
MR/M<)E=4D'_2(&'DKRI.:)(KL&IZPU>MT?UV%B+36:D6F*U"O=2\;GWL?2?P
ME^/TW 9/#^HLUY:@'EDL*S$;L*& E8JP_BL2GU-YF)GRSQ<O%$P\;Y]VG=!'
M[X61_I1X*H$"$'T&]<E4G>Y2=H-+ M"!ZX- WY);$=W'0W2"QICQH)+X; !3
MJ(,_:136J*XX;?APR- F1W@BKG:*26Z[<:H"LODW,!O0=XPGAS 3ESI45E^S
M"AY@7!X;[<R'S^=&US?(QVQY?=IK:+UAGGCK882T]">'_F<%?"N%_=D(@F4\
M%4'8MQ7J#)Z0B3)(PDH!XX\RAT,0'Q: ;PSB$T;*4TXD4[V QEE^$B\'XLI[
M3J\405*JN8(I3JYN<T+V" $M:!'LCDOX#H22AA[&F*GGX5D<[(QW'/E4^#+-
M3/KKW'3[B,[<]'DQTW?$A-$&*>B]RIX>[FTD\W?(C*.4 UW! HJ%:VMOE<GF
M-AX^H7TP+I)X_2<;7D2SZ24YM=DE.4/Q8"3=,JTO&/VLT0'L!BX-[NE4(E%V
M=9/.:]=/K"GNC]F(6+IAD6LFDR!6A8J7H&>RX"9H"_)NIDA:$2@V;-!?4/3R
MGT3&?#!-7X&&!%O2M7>BO2_#K5\%8!>Z"Z!,UAP;!R-,)J"K*:AMK"8%,604
M-@H:AJ#9/572 FOWH/)%MIJX5: .EWQ"%(2PWZA=Y=<D9"DLMI$"HQ.T=@=)
M$!!U05>F_1<G! -JD(B0RR%"@R;8D/=Y3!H-W21@/#+81)!G5(%-?F *NF(3
MV(>P'\[N!SML'D):\7!V9Q\:O\J\?!"HW."<U1X=\5GEYCS9CI>KD?ILGL9
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MM3K+ET\?O(M52?^&E?K#5\W_ 5!+ P04    "  Z@09;269QSE\"  #M!@
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M?_CF_U!+ 0(4 Q0    ( #J!!EM#P]U\0R$  #U; 0 7              "
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H<RTR,#(U,#@P-E]P<F4N>&UL4$L%!@     %  4 20$  &5$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>rcus-20250806_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rcus-20250806.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2025-08-06</startDate>
            <endDate>2025-08-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001724521</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Arcus Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38419</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-3898435</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">3928 Point Eden Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">694-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">RCUS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-23">2025-08-06</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2025-08-06</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
